


AMENDMENTS

1-3. (Cancelled)

4. (Currently Amended) A compound of the formula:



or a pharmaceutically acceptable salt thereof, wherein:

C1 A is absent or is selected from the group consisting of O,

S, NR_A, NR_ACR_BR_B', CR_B R_B'NR_A,

-CR_A=CR_B-, and C₃H₄; where R_A, R_B, and R_B' are independently selected at each occurrence from hydrogen and alkyl;

Z is oxygen or sulfur;

each R₃ and R₄ is independently

(a) selected from the group consisting of hydrogen;

halogen; hydroxy; amino; cyano; nitro;

-COOH; -CHO; optionally substituted alkyl; optionally

substituted alkenyl; optionally substituted alkynyl;

optionally substituted alkoxy; optionally substituted

alkylthio; optionally substituted alkyl ketone; optionally substituted alkylester; optionally substituted alkylsulfinyl; optionally substituted alkylsulfonyl; optionally substituted mono- or dialkylcarboxamide; optionally substituted $-S(O)_nNHalkyl$; optionally substituted $-S(O)_nN(alkyl)(alkyl)$; optionally substituted $-NHC(=O)alkyl$; optionally substituted $-NC(=O)(alkyl)(alkyl)$; optionally substituted $-NHS(O)_nalkyl$; optionally substituted $-NS(O)_n(alkyl)(alkyl)$; optionally substituted saturated heterocyclic ring or partially unsaturated heterocycle of from 5 to 8 atoms, which saturated heterocyclic ring or partially unsaturated heterocycle contains 1, 2, or 3 heteroatoms independently selected from N, O, and S; optionally substituted aryl having from 1 to 3 rings; and optionally substituted heteroaryl, said heteroaryl having from 1 to 3 rings, 5 to 8 ring members in each ring and, in at least one of said rings, from 1 to about 3 heteroatoms per ring independently selected from the group consisting of N, O, and S; or


(b) joined to a R_3 or R_4 not attached to the same carbon to form an optionally substituted aryl ring, a

saturated or partially unsaturated carbocyclic ring of from 5 to 8 members, which carbocyclic ring is optionally substituted, or a saturated, partially unsaturated, or aromatic heterocyclic ring of from 5 to 8 members, which heterocyclic ring is optionally substituted and contains 1, 2, or 3 heteroatoms selected from N, O, and S;

Ar₁ is selected from the group consisting of:

- C1
- (a) cyclohexyl, cyclopentyl, piperidinyl, piperazinyl, phenyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, benzimidazolyl, naphthyl, indolyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzo[b]thiophenyl, benz[d]isoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, and quinoxalinyl, each of which is optionally mono-, di-, or trisubstituted with R₅; and

- (b) bicyclic oxygen-containing groups of the formula:




optionally mono-, di-, or trisubstituted with R_5 , where L represents point of attachment and may be at any point on the benzene ring, and the oxygen-containing ring of the bicyclic oxygen-containing group consists of from 5 to 8 ring atoms, contains 1 or 2 oxygen atoms and remaining ring atoms are carbon;

Ar₂ is selected from the group consisting of:

- C1
- (a) cyclohexyl, cyclopentyl, piperidiny, piperaziny, pyrroly, furanyl, thienyl, pyrazoly, imidazoly, thiazoly, isothiazoly, oxazoly, isoxazoly, oxadiazoly, triazoly, tetrazoly, pyridyl, pyrimidyl, [pyraziny,] benzimidazoly, naphthyl, indoly, isoindoly, benzofuranyl, isobenzofuranyl, benzo[b]thiophenyl, benz[d]isoxazoly, quinoliny, isoquinoliny, cinnoliny, quinazoliny, and quinoxaliny, each of which is optionally mono-, di-, or trisubstituted with R_5 ; and

- (b) bicyclic oxygen-containing groups of the formula:



optionally mono-, di-, or trisubstituted with R_5 , where L represents point of attachment and may be at any point on the benzene ring, and the oxygen-containing

ring of the bicyclic oxygen-containing group consists of from 5 to 8 ring atoms, contains 1 or 2 oxygen atoms and remaining ring atoms are carbon;

R₅ is independently selected at each occurrence from the group consisting of halogen, nitro, halo(C₁₋₆)alkyl, halo(C₁₋₆)alkoxy, hydroxy, amino, C₁₋₆alkyl substituted with 0-2 R₆, C₂₋₆alkenyl substituted with 0-2 R₆, C₂₋₆alkynyl substituted with 0-2 R₆, C₁₋₆alkoxy and Y;

C1
R₆ is independently selected at each occurrence from the group consisting of halogen, hydroxy, cyano, C₁₋₄alkyl, C₁₋₄alkoxy, -S(O)_n(C₁₋₄alkyl), halo(C₁₋₄)alkyl, halo(C₁₋₄)alkoxy, CO(C₁₋₄alkyl), CONH(C₁₋₄alkyl), CON(C₁₋₄alkyl₁)(C₁₋₄alkyl₂) where alkyl₁ and alkyl₂ may be joined to form a saturated heterocyclic ring [heterocycle] of from 5 to 8 ring atoms and containing 1, 2, or 3 heteroatoms independently selected from N, O, and S, -XR₇, and Y;

X is independently selected at each occurrence from the group consisting of -CH₂-, -CHR₈-, -O-, -S(O)_n-, -NH-, -NR₈-, -C(=O)-, -C(=O)O-, -C(=O)NH-, -C(=O)NR₈-, -S(O)_nNH-, -S(O)_nNR₈-, NHC(=O)-, -NR₈C(=O)-, -NHS(O)_n-, and -NR₈S(O)_n-;

C

C1
R₇ and R₈ are independently selected at each occurrence from hydrogen, and straight, branched, and cyclic alkyl groups, and (cycloalkyl)alkyl groups, said straight, branched, and cyclic alkyl groups, and (cycloalkyl)alkyl groups consisting of 1 to 8 carbon atoms, and containing zero or one or more double or triple bonds, each of which 1 to 8 carbon atoms is unsubstituted or substituted with one or more substituent(s) independently selected from oxo, hydroxy, halogen, amino, cyano, nitro, haloalkyl, haloalkoxy, -O(alkyl), -NH(alkyl), -N(alkyl)(alkyl), -NHC(O)(alkyl), -N(alkyl)C(O)(alkyl), -NHS(O)_n(alkyl), -S(O)_n(alkyl), -S(O)_nNH(alkyl), -S(O)_nN(alkyl₃)(alkyl₄) where alkyl₃ and alkyl₄ are optionally joined to form a saturated heterocyclic ring [heterocycle] consisting of from 5 to 8 ring atoms and containing 1, 2, or 3 heteroatoms independently selected from N, O, and S, and Y';

Y and Y' are independently selected at each occurrence from 3- to 8-membered carbocyclic or heterocyclic groups which are saturated, unsaturated, or aromatic, which may be further substituted with one or more substituents independently selected from halogen, oxo,

hydroxy, amino, nitro, cyano, alkyl, alkoxy, haloalkyl, haloalkoxy, mono- or dialkylamino, and alkylthio;

wherein said 3- to 8-membered heterocyclic groups contain one or more heteroatom(s) independently selected from N, O, and S; and n is independently chosen at each occurrence from 0, 1, and 2.

C1 2/5. (Previously Amended) A compound or salt according to Claim ~~4~~, wherein:

R_A, R_B, and R_B' are independently selected at each occurrence from hydrogen and C₁₋₆alkyl;

each R₃ and R₄ is independently

(a) chosen from the group consisting of hydrogen, halogen, cyano, nitro, halo(C₁₋₆)alkyl, halo(C₁₋₆)alkoxy, hydroxy, amino, C₁₋₆alkyl substituted with 0-2 R₆, C₂₋₆alkenyl substituted with 0-2 R₆; C₂₋₆alkynyl substituted with 0-2 R₆; C₁₋₆alkoxy substituted with 0-2 R₆, -NH(C₁₋₆alkyl) substituted with 0-2 R₆, -N(C₁₋₆alkyl)(C₁₋₆alkyl) where each C₁₋₆alkyl is independently substituted with 0-2 R₆, -XR₇, and Y; or

(b) joined to a R_3 or R_4 not attached to the same carbon to form an aryl ring substituted with 0-3 R_6 , a saturated or partially unsaturated carbocyclic ring of from 5 to 8 members, which carbocyclic ring is substituted with 0-2 R_6 , or a saturated, partially unsaturated, or aromatic heterocyclic ring of from 5 to 8 members, which heterocyclic ring is substituted with 0-2 R_6 and contains 1, 2, or 3 heteroatoms independently selected from N, O, and S;

C1 R_7 and R_8 are independently selected at each occurrence from hydrogen, and straight, branched, and cyclic alkyl groups, and (cycloalkyl)alkyl groups, said straight, branched, and cyclic alkyl groups, and (cycloalkyl)alkyl groups consisting of 1 to 8 carbon atoms, and containing zero or one or more double or triple bonds, each of which 1 to 8 carbon atoms is unsubstituted or substituted with one or more substituent(s) independently selected from oxo, hydroxy, halogen, amino, cyano, nitro, haloalkyl, haloalkoxy, -O(alkyl), -NH(alkyl), -N(alkyl)(alkyl), -NHC(O)(C₁₋₄alkyl), -N(C₁₋₄alkyl)C(O)(C₁₋₄alkyl), -NHS(O)_n(C₁₋₄alkyl), -S(O)_n(C₁₋₄alkyl), -S(O)_nNH(C₁₋₄alkyl), -S(O)_nN(C₁₋₄alkyl)₃(C₁₋₄alkyl)₄ where C₁₋₄alkyl₃

C


C1 and C₁₋₄alkyl₄ are optionally joined to form a saturated heterocyclic ring [heterocycle] consisting of from 5 to 8 ring atoms and containing 1, 2, or 3 heteroatoms independently selected from N, O, and S, and Y'; and Y and Y' are independently selected at each occurrence from 3- to 8-membered carbocyclic or heterocyclic groups which are saturated, unsaturated, or aromatic, which are unsubstituted or substituted with one or more substituents independently selected from halogen, oxo, hydroxy, amino, nitro, cyano, C₁₋₄alkyl, C₁₋₄alkoxy, halo(C₁₋₄)alkyl, halo(C₁₋₄)alkoxy, mono- or di(C₁₋₄)alkylamino, and C₁₋₄alkylthio;

wherein said 3- to 8-membered heterocyclic groups contain one or more heteroatom(s) independently selected from N, O, and S.

3/~~6~~. (Original) A compound or salt according to Claim 1/~~4~~, wherein Z is oxygen.

[7. (Cancelled)]

T,9001
4/8. (Currently Amended) A compound of the formula:



or a pharmaceutically acceptable salt thereof, wherein:

A is absent or is selected from the group consisting of O,

S, NR_A , $\text{CR}_B\text{R}_{B'}$, $\text{NR}_A\text{CR}_B\text{R}_{B'}$, $\text{CR}_B\text{R}_{B'}\text{NR}_A$, $-\text{CR}_A=\text{CR}_B-$, and C_3H_4 ;

where R_A , R_B , and $\text{R}_{B'}$ are independently selected at each occurrence from hydrogen or alkyl;

each R_3 and R_4 is independently

(a) selected from the group consisting of hydrogen; halogen; hydroxy; amino; cyano; nitro;

$-\text{COOH}$; $-\text{CHO}$, optionally substituted alkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted alkoxy; optionally substituted mono or dialkylamino; optionally substituted alkylthio; optionally substituted alkyl ketone; optionally substituted alkylester; optionally substituted alkylsulfinyl; optionally substituted alkylsulfonyl; optionally substituted mono- or dialkylcarboxamide; optionally substituted $-\text{S}(\text{O})_n\text{NHalkyl}$; optionally substituted $-\text{S}(\text{O})_n\text{N(alkyl)(alkyl)}$; optionally substituted $-\text{NHC}(=\text{O})\text{alkyl}$; optionally

substituted -NC(=O)(alkyl)(alkyl); optionally substituted -NHS(O)_nalkyl; optionally substituted -NS(O)_n(alkyl)(alkyl); optionally substituted saturated heterocyclic ring or partially unsaturated heterocycle of from 5 to 8 atoms, which saturated heterocyclic ring or partially unsaturated heterocycle contains 1, 2, or 3 heteroatoms independently selected from N, O, and S; optionally substituted aryl having from 1 to 3 rings; and optionally substituted heteroaryl, said heteroaryl having from 1 to 3 rings, 5 to 8 ring members in each ring and, in at least one of said rings, from 1 to about 3 heteroatoms per ring independently selected from the group consisting of N, O, and S; or

- (b) joined to a R₃ or R₄ not attached to the same carbon to form an optionally substituted aryl ring; a saturated or partially unsaturated carbocyclic ring of from 5 to 8 members, which carbocyclic ring is optionally substituted; or a saturated, partially unsaturated, or aromatic heterocyclic ring of from 5 to 8 members, which heterocyclic ring is optionally substituted and contains 1, 2, or 3 heteroatoms independently selected from N, O, and S;

Ar₁ [and Ar₂ are independently] is selected from the group consisting of:

C1 (a) cyclohexyl, cyclopentyl, piperidinyl, piperazinyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, benzimidazolyl, naphthyl, indolyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzo[b]thiophenyl, benz[d]isoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, and quinoxalinyl; wherein Ar₁ is optionally mono-, di-, or trisubstituted with R₅, and Ar₂ is optionally mono-, di-, or trisubstituted with R₉;


Ar₂ is selected from the group consisting of:

cyclohexyl, cyclopentyl, piperidinyl, piperazinyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, benzimidazolyl, naphthyl, indolyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzo[b]thiophenyl, benz[d]isoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, and quinoxalinyl; wherein Ar₁ is optionally

C

mono-, di-, or trisubstituted with R_5 , and Ar_2 is optionally mono-, di-, or trisubstituted with R_9 ; and

(b) groups of the formula:



optionally mono-, di-, or trisubstituted with R_5 , where L represents point of attachment and may be at any point on the benzene ring, and the oxygen-containing ring of the bicyclic oxygen-containing group consists of from 5 to 8 ring atoms, contains 1 or 2 oxygen atoms and remaining ring atoms are carbon;

R_5 is independently selected at each occurrence from the group consisting of cyano, nitro, haloalkyl, haloalkoxy, hydroxy, amino, alkyl substituted with 0-2 R_6 , alkenyl substituted with 0-2 R_6 , alkynyl substituted with 0-2 R_6 , alkoxy and Y;

R_9 is independently selected at each occurrence from the group consisting of nitro, haloalkoxy, hydroxy, amino, alkyl substituted with 0-2 R_6 , alkenyl substituted with 0-2 R_6 , alkynyl substituted with 0-2 R_6 , alkoxy substituted with 0-2 R_6 , and Y;

R_6 is independently selected at each occurrence from the group consisting of halogen, hydroxy, cyano, alkyl,

alkoxy, $-S(O)_n(\text{alkyl})$, haloalkyl, haloalkoxy, $CO(\text{alkyl})$, $CONH(\text{alkyl})$, $CON(\text{alkyl}_1)(\text{alkyl}_2)$ where alkyl_1 and alkyl_2 may be joined to form a saturated heterocyclic ring [heterocycle] of from 5 to 8 ring atoms and containing 1, 2, or 3 heteroatoms independently selected from N, O, and S, $-XR_7$, and Y;

C1 X is independently selected at each occurrence from the group consisting of $-CH_2-$, $-CHR_8-$, $-O-$, $-S(O)_n-$, $-NH-$, $-NR_8-$, $-C(=O)-$, $-C(=O)O-$, $-C(=O)NH-$, $-C(=O)NR_8-$, $-S(O)_nNH-$, $-S(O)_nNR_8-$, $NHC(=O)-$, $-NR_8C(=O)-$, $-NHS(O)_n-$, and $-NR_8S(O)_n-$;

R_7 and R_8 are independently selected at each occurrence from hydrogen, and straight, branched, and cyclic alkyl groups, and (cycloalkyl)alkyl groups, said straight, branched, and cyclic alkyl groups, and (cycloalkyl)alkyl groups consisting of 1 to 8 carbon atoms, and containing zero or one or more double or triple bonds, each of which 1 to 8 carbon atoms is unsubstituted or substituted with one or more substituent(s) independently selected from oxo, hydroxy, halogen, amino, cyano, nitro, haloalkyl, haloalkoxy, $-O(\text{alkyl})$,

C

-NH(alkyl), -N(alkyl)(alkyl), -NHC(O)(alkyl),
-N(alkyl)C(O)(alkyl), -NHS(O)_n(alkyl), -S(O)_n(alkyl),
-S(O)_nNH(alkyl), -S(O)_nN(alkyl₃)(alkyl₄) where alkyl₃
and alkyl₄ are optionally joined to form a saturated
heterocyclic ring [heterocycle] consisting of from 5
to 8 ring atoms and containing 1, 2, or 3 heteroatoms
independently selected from N, O, and S, and Y';


C1 Y and Y' are independently selected at each occurrence from
3- to 8-membered carbocyclic or heterocyclic groups
which are saturated, unsaturated, or aromatic, which
are unsubstituted or substituted with one or more
substituents independently selected from halogen, oxo,
hydroxy, amino, nitro, cyano, alkyl, alkoxy,
haloalkyl, haloalkoxy, mono- or dialkylamino, and
alkylthio;

wherein said 3- to 8-membered heterocyclic groups
contain one or more heteroatom(s) independently selected
from N, O, and S; and

n is independently chosen at each occurrence from 0, 1, and
2.

5/. (Previously Amended) A compound of the formula:

C



or a pharmaceutically acceptable salt thereof, wherein:

G, Q, T, and W are the same or different and are selected from the group consisting of N, CH, and CR₅, wherein T or W or both is N;

C1
A is absent or is selected from the group consisting of O, S, NR_A, CR_BR_{B'}, NR_ACR_BR_{B'}, CR_B R_{B'}NR_A, -CR_A=CR_B-, and C₃H₄; where R_A, R_B, and R_{B'} are independently selected at each occurrence from hydrogen and alkyl;

Z is oxygen or sulfur;

each R₃ and R₄ is independently

- (a) selected from the group consisting of hydrogen; halogen; hydroxy; amino; cyano; nitro; -COOH; -CHO, optionally substituted C₁₋₆alkyl; optionally substituted C₂₋₆alkenyl; optionally substituted C₂₋₆alkynyl; optionally substituted C₁₋₆alkoxy; optionally substituted mono or di(C₁₋₆)alkylamino; optionally substituted C₁₋₆alkylthio; optionally substituted C₁₋₆alkyl ketone; optionally substituted C₁₋₆alkylester; optionally substituted C₁₋

C1
alkylsulfinyl; optionally substituted C₁₋₆alkylsulfonyl; optionally substituted mono- or di(C₁₋₆)alkylcarboxamide; optionally substituted -S(O)_nNH C₁₋₆alkyl; optionally substituted -S(O)_nN(C₁₋₆alkyl)(C₁₋₆alkyl); optionally substituted -NHC(=O) C₁₋₆alkyl; optionally substituted -NC(=O)(C₁₋₆alkyl)(C₁₋₆alkyl); optionally substituted -NHS(O)_nC₁₋₆alkyl; optionally substituted -NS(O)_n(C₁₋₆alkyl)(C₁₋₆alkyl); optionally substituted saturated heterocyclic ring or partially unsaturated heterocycle of from 5 to 8 atoms, which saturated heterocyclic ring or partially unsaturated heterocycle contains 1, 2, or 3 heteroatoms independently selected from N, O, and S; optionally substituted aryl having from 1 to 3 rings; and optionally substituted heteroaryl, said heteroaryl having from 1 to 3 rings, 5 to 8 ring members in each ring and, in at least one of said rings, from 1 to about 3 heteroatoms per ring independently selected from the group consisting of N, O, and S; or

- (b) joined to a R₃ or R₄ not attached to the same carbon to form an optionally substituted aryl ring; a saturated or partially unsaturated carbocyclic ring of from 5 to 8 members, which carbocyclic ring is

optionally substituted; or a saturated, partially unsaturated, or aromatic heterocyclic ring of from 5 to 8 members, which heterocyclic ring is optionally substituted and contains 1, 2, or 3 heteroatoms independently selected from N, O, and S;

C1 R₅ represents 1 to 3 substituents independently selected at each occurrence from the group consisting of cyano, hydroxy, amino, C₃₋₆ alkyl substituted with 0-2 R₆, C₂₋₆ alkenyl substituted with 0-2 R₆, C₂₋₆ alkynyl substituted with 0-2 R₆, C₃₋₆ alkoxy, -NH(C₁₋₆alkyl) substituted with 0-2 R₆, -N(C₁₋₆alkyl)(C₁₋₆alkyl) where each alkyl is independently substituted with 0-2 R₆, -XR₇, and Y;

R₉ represents 0 to 3 substituents independently selected at each occurrence from the group consisting of halogen, nitro, halo(C₁₋₆)alkyl, halo(C₁₋₆)alkoxy, hydroxy, amino, C₁₋₆alkyl substituted with 0-2 R₆, C₂₋₆alkenyl substituted with 0-2 R₆, C₂₋₆alkynyl substituted with 0-2 R₆, C₁₋₆alkoxy substituted with 0-2 R₆, and Y;

R₆ is independently selected at each occurrence from the group consisting of halogen, hydroxy, cyano, C₁₋₄alkyl, C₁₋₄alkoxy, -S(O)_n(C₁₋₄alkyl), halo(C₁₋₄)alkyl, halo(C₁₋₄)alkoxy, CO(C₁₋₄alkyl), CONH(C₁₋₄alkyl), CON(C₁₋

$_4\text{alkyl}_1)(\text{C}_{1-4}\text{alkyl}_2)$ where alkyl_1 and alkyl_2 may be joined to form a saturated heterocyclic ring [heterocycle] of from 5 to 8 ring atoms and containing 1, 2, or 3 heteroatoms independently selected from N, O, and S, $-\text{XR}_7$, and Y;

C1 X is independently selected at each occurrence from the group consisting of $-\text{CH}_2-$, $-\text{CHR}_8-$, $-\text{O}-$, $-\text{S}(\text{O})_n-$, $-\text{NH}-$, $-\text{NR}_8-$, $-\text{C}(=\text{O})-$, $-\text{C}(=\text{O})\text{O}-$, $-\text{C}(=\text{O})\text{NH}-$, $-\text{C}(=\text{O})\text{NR}_8-$, $-\text{S}(\text{O})_n\text{NH}-$, $-\text{S}(\text{O})_n\text{NR}_8-$, $\text{NHC}(=\text{O})-$, $-\text{NR}_8\text{C}(=\text{O})-$, $-\text{NHS}(\text{O})_n-$, and $-\text{NR}_8\text{S}(\text{O})_n-$;

R_7 and R_8 are independently selected at each occurrence from hydrogen, and straight, branched, and cyclic alkyl groups, and (cycloalkyl)alkyl groups, said straight, branched, and cyclic alkyl groups, and (cycloalkyl)alkyl groups consisting of 1 to 8 carbon atoms, and containing zero or one or more double or triple bonds, each of which 1 to 8 carbon atoms is unsubstituted or substituted with one or more substituent(s) independently selected from oxo, hydroxy, halogen, amino, cyano, nitro, haloalkyl, haloalkoxy, $-\text{O}(\text{C}_{1-4}\text{alkyl})$, $-\text{NH}(\text{C}_{1-4}\text{alkyl})$, $-\text{N}(\text{C}_{1-4}\text{alkyl})(\text{C}_{1-4}\text{alkyl})$, $-\text{NHC}(\text{O})(\text{C}_{1-4}\text{alkyl})$, $-\text{N}(\text{C}_{1-4}\text{alkyl})\text{C}(\text{O})(\text{C}_{1-4}\text{alkyl})$, $-\text{NHS}(\text{O})_n(\text{C}_{1-4}\text{alkyl})$, $-\text{S}(\text{O})_n(\text{C}_{1-4}\text{alkyl})$,

C

$C_{1-4}alkyl$), $-S(O)_nNH(C_{1-4}alkyl)$, $-S(O)_nN(C_{1-4}alkyl_3)(C_{1-4}alkyl_4)$ where $C_{1-4}alkyl_3$ and $C_{1-4}alkyl_4$ are optionally joined to form a saturated heterocyclic ring [heterocycle] consisting of from 5 to 8 ring atoms and containing 1, 2, or 3 heteroatoms independently selected from N, O, and S, and Y';

C1 Y and Y' are independently selected at each occurrence from 3- to 8-membered carbocyclic or heterocyclic groups which are saturated, unsaturated, or aromatic, which are unsubstituted or substituted with one or more substituents independently selected from halogen, oxo, hydroxy, amino, nitro, cyano, $C_{1-4}alkyl$, $C_{1-4}alkoxy$, halo(C_{1-4})alkyl, halo(C_{1-4})alkoxy, mono- or di(C_{1-4})alkylamino, and $C_{1-4}alkylthio$;

wherein said 3- to 8-membered heterocyclic groups contain one or more heteroatom(s) independently selected from N, O, and S; and

n is independently chosen at each occurrence from 0, 1, and 2.

~~6~~ 10. (Original) A compound according to Claim ~~9~~⁵, which is 4-(3-Chloro-2-pyridinyl)-N-[4(isopropyl)phenyl]-2-

methylthio-1-piperazinecarboxamide, or a pharmaceutically acceptable salt thereof.

~~7~~ ⁵1. (Original) A compound according to Claim ~~8~~, wherein R_3 and R_4 are independently selected at each occurrence from the group consisting of hydrogen and C_{1-6} alkyl.

C1 ~~8~~ ⁷12. (Original) A compound according to Claim ~~11~~, wherein G and Q are selected from the group consisting of CH and CR_5 .

~~9~~ ⁷13. (Original) A compound according to Claim ~~11~~, wherein G, Q, and W are independently selected at each occurrence from the group consisting of CH and CR_5 ; and T is N.

¹⁰ ~~14~~ ⁹14. (Original) A compound according to Claim ~~13~~ wherein R_3 and R_4 are hydrogen; and A is selected from the group consisting of NH, $-CH=CH-$, and $-CH_2NH-$.

¹⁰ ¹² ~~15~~15. (Original) A compound or salt according to Claim ~~14~~, wherein R_6 is independently selected at each occurrence

from the group consisting of halogen, hydroxy, C₁₋₄ alkyl, C₁₋₄ alkoxy, -NH(C₁₋₄alkyl), and -N(C₁₋₄ alkyl)(C₁₋₄ alkyl).

¹²
~~16~~. (Original) A compound according to Claim ¹⁰~~14~~, which is 4-(3-Trifluoromethyl-2-pyridinyl)-N-(3-methoxy-4-hydroxyphenylmethyl)-1-piperazinecarboxamide, or a pharmaceutically acceptable salt thereof.

C1 ¹³
~~17~~. (Original) A compound according to Claim ¹⁰~~14~~, which is 4-(3-Nitro-pyridinyl)-N-[4-(n-butyl)phenyl]-1-piperazinecarboxamide, or a pharmaceutically acceptable salt thereof.

¹⁴
~~18~~. (Original) A compound according to Claim ¹⁰~~14~~, which is 4-(3-Trifluoromethyl-2-pyridinyl)-N-[4-(n-butyl)phenyl]-1-piperazinecarboxamide, or a pharmaceutically acceptable salt thereof.

¹⁶
~~19~~. (Original) A compound according to Claim ¹⁰~~14~~, which is 4-(3-Methyl-2-pyridinyl)-N-[4-(isopropyl)phenyl]-1-piperazinecarboxamide, or a pharmaceutically acceptable salt thereof.

¹⁶
~~20~~. (Original) A compound according to Claim ¹⁰~~14~~, which is 4-(3-Methyl-2-pyridinyl)-N-[4-(n-butyl)phenyl]-1-piperazinecarboxamide, or a pharmaceutically acceptable salt thereof.

¹⁷
~~21~~. (Original) A compound according to Claim ¹⁰~~14~~, which is 4-(3-Chloro-5-trifluoromethyl-2-pyridinyl)-N-[4-(isopropyl)phenyl]-1-piperazinecarboxamide, or a pharmaceutically acceptable salt thereof.

C1
¹⁸
~~22~~. (Original) A compound according to Claim ¹⁰~~14~~, which is 4-(3-Chloro-2-pyridinyl)-N-[4-(isopropyl)phenyl]-1-piperazinecarboxamide, or a pharmaceutically acceptable salt thereof.


¹⁹
~~23~~. (Original) A compound according to Claim ¹⁰~~14~~, which is 4-(3,5-Dichloro-2-pyridinyl)-N-[4-(isopropyl)phenyl]-1-piperazinecarboxamide, or a pharmaceutically acceptable salt thereof.

NE
was
cancelled
Amdt B
24. (Original) A compound according to claim 13, which is 4-(3-Cyano-2-pyridinyl)-N-[4-(isopropyl)phenyl]-1-

piperazinecarboxamide, or a pharmaceutically acceptable salt thereof.

²⁰
~~25~~. (Original) The compound according to claim ⁹~~13~~, which is 4-(3-Chloro-2-pyridinyl)-N-[4-(isopropyl)phenyl]-2-methyl-1-piperazinecarboxamide.

²¹
~~26~~. (Previously Amended) A compound of the formula:



or a pharmaceutically acceptable salt thereof, wherein:

A is selected from the group consisting of NH, -CH=CH-, and CH₂NH;

R₄ is independently chosen from hydrogen and C₁₋₄ alkyl;

R₅ represents 0 to 2 substituents independently chosen at each occurrence from the group consisting of halogen, cyano, nitro, halo(C₁₋₆)alkyl, halo(C₁₋₆)alkoxy, hydroxy, amino, C₁₋₆alkyl substituted with 0-2 R₆, C₂₋₆alkenyl substituted with 0-2 R₆, C₂₋₆alkynyl substituted with 0-2 R₆, C₁₋₆alkoxy, -NH(C₁₋₆alkyl) substituted with 0-2 R₆, and -N(C₁₋₆alkyl)(C₁₋₆alkyl)

where each C₁₋₆alkyl is independently substituted with
0-2 R₆;


C1
R₉ represents 0 to 2 substituents and is independently
chosen at each occurrence from the group consisting of
halogen, nitro, halo(C₁₋₆)alkyl, halo(C₁₋₆)alkoxy,
hydroxy, amino, C₁₋₆alkyl substituted with 0-2 R₆, C₂₋₆
alkenyl substituted with 0-2 R₆, C₂₋₆alkynyl
substituted with 0-2 R₆, and C₁₋₆alkoxy substituted with
0-2 R₆;

R_{5A} is independently selected from the group consisting of
halogen, cyano, nitro, halo(C₁₋₆)alkyl, halo(C₁₋₆)
alkoxy, hydroxy, amino, C₁₋₆ alkyl, C₁₋₆ alkoxy, -
NH(C₁₋₆ alkyl), and -N(C₁₋₆ alkyl)(C₁₋₆ alkyl);

R_{9B} is independently selected from the group consisting of
halogen, nitro, halo(C₁₋₆)alkoxy, hydroxy, amino, C₁₋₆
alkyl, and C₁₋₆ alkoxy; and

R₆ is independently selected at each occurrence the group
consisting of halogen, hydroxy, C₁₋₄alkyl, C₁₋₄alkoxy, -
NH(C₁₋₄ alkyl), and -N(C₁₋₄ alkyl)(C₁₋₄ alkyl).

~~28~~
27. (Previously Amended) A compound of the formula:



or a pharmaceutically acceptable salt thereof, wherein:

A is selected from the group consisting of a single bond,
S, NR_A, NR_ACHR_B, CHR_BNR_A, -CR_A=CR_B-, and C₃H₄; where R_A
and R_B are independently selected at each occurrence
from the group consisting of hydrogen and alkyl;

each R₃ and R₄ is independently

- C1
- (a) selected from the group consisting of hydrogen;
halogen; hydroxy; amino; cyano; nitro;
-COOH; -CHO, optionally substituted alkyl; optionally
substituted alkenyl; optionally substituted alkynyl;
optionally substituted alkoxy; optionally substituted
mono or dialkylamino; optionally substituted
alkylthio; optionally substituted alkyl ketone;
optionally substituted alkylester; optionally
substituted alkylsulfinyl; optionally substituted
alkylsulfonyl; optionally substituted mono- or di-
alkylcarboxamide; optionally substituted -S(O)_nNHalkyl;
optionally substituted -S(O)_nN(alkyl)(alkyl);

C1
optionally substituted -NHC(=O)alkyl; optionally substituted -NC(=O)(alkyl)(alkyl); optionally substituted -NHS(O)_nalkyl; optionally substituted -NS(O)_n(alkyl)(alkyl); optionally substituted saturated heterocyclic ring or partially unsaturated heterocycle of from 5 to 8 atoms, which saturated heterocyclic ring or partially unsaturated heterocycle contains 1, 2, or 3 heteroatoms independently selected from N, O, and S; optionally substituted aryl having from 1 to 3 rings; and optionally substituted heteroaryl, said heteroaryl having from 1 to 3 rings, 5 to 8 ring members in each ring and, in at least one of said rings, from 1 to about 3 heteroatoms per ring independently selected from the group consisting of N, O, and S; or

- (b) joined to a R₃ or R₄ not attached to the same carbon to form an optionally substituted aryl ring; a saturated or partially unsaturated carbocyclic ring of from 5 to 8 members, which carbocyclic ring is optionally substituted; or a saturated, partially unsaturated, or aromatic heterocyclic ring of from 5 to 8 members, which heterocyclic ring is optionally

substituted and contains 1, 2, or 3 heteroatoms independently selected from N, O, and S;

R₅ represents 0-3 substituents independently selected at each occurrence from the group consisting of cyano, nitro, haloalkyl, haloalkoxy, C₂₋₆ alkenyl substituted with 0-2 R₆, and C₂₋₆ alkynyl substituted with 0-2 R₆;

C1
R₉ represents 0-3 substituents independently selected at each occurrence from the group consisting of bromo, haloalkyl, haloalkoxy, hydroxy, C₂₋₆ alkyl substituted with 0-2 R₆, C₂₋₆ alkenyl substituted with 0-2 R₆, C₂₋₆ alkynyl substituted with 0-2 R₆, and C₂₋₆ alkoxy;

R₆ is independently selected at each occurrence from the group consisting of halogen, hydroxy, cyano, alkyl, alkoxy, -S(O)_n(alkyl), haloalkyl, haloalkoxy, CO(alkyl), CONH(alkyl), CON(alkyl₁)(alkyl₂) where alkyl₁ and alkyl₂ may be joined to form a saturated heterocyclic ring [heterocycle] of from 5 to 8 ring atoms and containing 1, 2, or 3 heteroatoms independently selected from N, O, and S, -XR₇, and Y;

X is independently selected at each occurrence from the group consisting of -CH₂-, -CHR₈-, -O-, -S(O)_n-, -NH-, -NR₈-, -C(=O)-, -C(=O)O-, -C(=O)NH-, -C(=O)NR₈-, -S(O)_nNH-,

-S(O)_nNR₈-, NHC(=O)-, -NR₈C(=O)-, -NHS(O)_n-, and -NR₈S(O)_n-;

C1
R₇ and R₈ are independently selected at each occurrence from straight, branched, and cyclic alkyl groups, and (cycloalkyl)alkyl groups, said straight, branched, and cyclic alkyl groups, and (cycloalkyl)alkyl groups consisting of 3 to 8 carbon atoms, and containing zero or one or more double or triple bonds, each of which 3 to 8 carbon atoms is unsubstituted or substituted with one or more substituent(s) independently selected from oxo, hydroxy, halogen, amino, cyano, nitro, haloalkyl, haloalkoxy, -O(alkyl), -NH(alkyl), -N(alkyl)(alkyl), -NHC(O)(alkyl), -N(alkyl)C(O)(alkyl), -NHS(O)_n(alkyl), -S(O)_n(alkyl), -S(O)_nNH(alkyl), -S(O)_nN(alkyl₃)(alkyl₄) where alkyl₃ and alkyl₄ are optionally joined to form a saturated heterocyclic ring [heterocycle] consisting of from 5 to 8 ring atoms and containing 1, 2, or 3 heteroatoms independently selected from N, O, and S, and Y';

Y and Y' are independently selected at each occurrence from 3- to 8-membered carbocyclic or heterocyclic groups which are saturated, unsaturated, or aromatic, which are unsubstituted or substituted with one or more

substituents independently selected from halogen, oxo, hydroxy, amino, nitro, cyano, alkyl, alkoxy, haloalkyl, haloalkoxy, mono- or dialkylamino, and alkylthio;

wherein said 3- to 8-membered heterocyclic groups contain one or more heteroatom(s) independently selected from N, O, and S; and

n is independently chosen at each occurrence from 0, 1, and

2.

23

~~24~~


21 C1
28. (Original) A compound or salt according to Claim 22/27 in which R₃ and R₄ are independently selected at each occurrence from the group consisting of hydrogen and C₁₋₆ alkyl.

24

28/27
29. (Original) A compound or salt according to claim 28/27, wherein A is selected from the group consisting of NH, -CH=CH-, and CH₂NH; R₃ is hydrogen and R₄ is independently chosen at each occurrence from hydrogen and methyl; and R₆ is independently selected at each occurrence from the group consisting of halogen, hydroxy, C₁₋₄ alkyl, C₁₋₄ alkoxy, -NH(C₁₋₄ alkyl), and -N(C₁₋₄ alkyl)(C₁₋₄ alkyl).

C

25
30. (Previously Amended) A compound of the formula:



or a pharmaceutically acceptable salt thereof, wherein:

A is selected from the group consisting of NH, -CH=CH-, and CH₂NH;

C1
R₄ is independently selected at each occurrence from hydrogen and C₁₋₄alkyl;


R₅ represents 0 to 2 substituents independently selected at each occurrence from the group consisting of halogen, cyano, nitro, halo(C₁₋₆)alkyl, halo(C₁₋₆)alkoxy, amino, C₂₋₆alkenyl substituted with 0-2 R₆, and C₂₋₆alkynyl substituted with 0-2 R₆;

R₉ represents 0 to 2 substituents and is independently selected at each occurrence from the group consisting of halogen, nitro, halo(C₁₋₆)alkyl, halo(C₁₋₆)alkoxy, hydroxy, amino, C₁₋₆alkyl substituted with 0-2 R₆, C₂₋₆alkenyl substituted with 0-2 R₆, C₂₋₆alkynyl substituted with 0-2 R₆, and C₁₋₆alkoxy substituted with 0-2 R₆;

R_{5A} is independently selected from the group consisting of halogen, cyano, nitro, trifluoromethyl,

trifluoromethoxy, hydroxy, amino, C₁₋₆ alkyl, C₁₋₆ alkoxy, -NH(C₁₋₆ alkyl), and -N(C₁₋₆ alkyl)(C₁₋₆ alkyl);
R_{9B} is independently selected from the group consisting of
trifluoromethoxy, hydroxy, C₂₋₆ alkyl, and C₂₋₆ alkoxy;
and
R₆ is independently selected at each occurrence from the
group consisting of halogen, hydroxy, C₁₋₄ alkyl, and
C₁₋₄ alkoxy.

26
31. (Previously Amended) A compound of the formula:



or a pharmaceutically acceptable salt thereof, wherein the
compound or pharmaceutically acceptable salt thereof
exhibits an EC50 or K_i of 1 micromolar or less in a
standard assay of capsaicin receptor mediated calcium
mobilization; and wherein

A is absent or is selected from the group consisting of O,
S, NR_A, NR_ACR_BR_B', CR_B R_B'NR_A, -CR_A=CR_B-, and C₃H₄; where
R_A, R_B, and R_B' are independently selected at each
occurrence from hydrogen and C₁₋₆ alkyl;

Z is oxygen or sulfur;

each R₃ and R₄ is independently

(a) selected from the group consisting of hydrogen, halogen, cyano, nitro, halo(C₁₋₆)alkyl, halo(C₁₋₆)alkoxy, hydroxy, amino, C₁₋₆alkyl substituted with 0-2 R₆, C₂₋₆alkenyl substituted with 0-2 R₆; C₂₋₆alkynyl substituted with 0-2 R₆; C₁₋₆alkoxy substituted with 0-2 R₆, -NH(C₁₋₆alkyl) substituted with 0-2 R₆, -N(C₁₋₆alkyl)(C₁₋₆alkyl) where each C₁₋₆alkyl is independently substituted with 0-2 R₆, -XR₇, and Y; or


C1
(b) joined to a R₃ or R₄ not attached to the same carbon to form an aryl ring substituted with 0-3 R₆, a saturated or partially unsaturated carbocyclic ring of from 5 to 8 members, which carbocyclic ring is substituted with 0-2 R₆, or a saturated, partially unsaturated, or aromatic heterocyclic ring of from 5 to 8 members, which heterocyclic ring is substituted with 0-2 R₆ and contains 1, 2, or 3 heteroatoms independently selected from N, O, and S;

Ar₁ is selected from the group consisting of:

(a) cyclohexyl, cyclopentyl, piperidiny, piperazinyl, phenyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl,

pyridyl, pyrimidyl, pyrazinyl, benzimidazolyl,
 naphthyl, indolyl, isoindolyl, benzofuranyl,
 isobenzofuranyl, benzo[b]thiophenyl,
 benz[d]isoxazolyl, quinolinyl, isoquinolinyl,
 cinnolinyl, quinazolinyl, and quinoxalinyl, each of
 which is optionally mono-, di-, or trisubstituted
 with R₅; and

(b) bicyclic oxygen-containing groups of the formula:




optionally mono-, di-, or trisubstituted with R₅, where
 L represents point of attachment and may be at any
 point on the benzene ring, and the oxygen-containing
 ring of the bicyclic oxygen-containing group consists
 of from 5 to 8 ring atoms, contains 1 or 2 oxygen
 atoms and remaining ring atoms are carbon;

Ar₂ is selected from the group consisting of:

- (a) cyclohexyl, cyclopentyl, piperidinyl,
 piperazinyl, pyrrolyl, furanyl, thienyl, pyrazolyl,
 imidazolyl, thiazolyl, isothiazolyl, oxazolyl,
 isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl,
 pyridyl, pyrimidyl, [pyrazinyl,] benzimidazolyl,
 naphthyl, indolyl, isoindolyl, benzofuranyl,

isobenzofuranyl, benzo[b]thiophenyl,
benz[d]isoxazolyl, quinolinyl, isoquinolinyl,
cinnolinyl, quinazolinyl, and quinoxalinyl, each of
which is optionally mono-, di-, or trisubstituted with
R₅; and

(b) bicyclic oxygen-containing groups of the formula:



optionally mono-, di-, or trisubstituted with R₅, where
L represents point of attachment and may be at any
point on the benzene ring, and the oxygen-containing
ring of the bicyclic oxygen-containing group consists
of from 5 to 8 ring atoms, contains 1 or 2 oxygen
atoms and remaining ring atoms are carbon;

R₅ is independently selected at each occurrence from the
group consisting of halogen, nitro, halo(C₁₋₆)alkyl,
halo(C₁₋₆)alkoxy, hydroxy, amino, C₁₋₆alkyl substituted
with 0-2 R₆, C₂₋₆alkenyl substituted with 0-2 R₆, C₂₋₆
alkynyl substituted with 0-2 R₆, C₁₋₆alkoxy and Y;

R₆ is independently selected at each occurrence from the
group consisting of halogen, hydroxy, cyano, C₁₋₄alkyl,
C₁₋₄alkoxy, -S(O)_n(C₁₋₄alkyl), halo(C₁₋₄)alkyl, halo(C₁₋₄)
alkoxy, CO(C₁₋₄alkyl), CONH(C₁₋₄alkyl), CON(C₁₋

alkyl₁)(C₁₋₄alkyl₂) where alkyl₁ and alkyl₂ may be joined to form a saturated heterocyclic ring [heterocycle] of from 5 to 8 ring atoms and containing 1, 2, or 3 heteroatoms independently selected from N, O, and S, -XR₇, and Y;

C1
X is independently selected at each occurrence from the group consisting of -CH₂-, -CHR₈-, -O-, -S(O)_n-, -NH-, -NR₈-, -C(=O)-, -C(=O)O-, -C(=O)NH-, -C(=O)NR₈-, -S(O)_nNH-, -S(O)_nNR₈-, NHC(=O)-, -NR₈C(=O)-, -NHS(O)_n-, and -NR₈S(O)_n-;

R₇ and R₈ are independently selected at each occurrence from hydrogen, and straight, branched, and cyclic alkyl groups, and (cycloalkyl)alkyl groups, said straight, branched, and cyclic alkyl groups, and (cycloalkyl)alkyl groups consisting of 1 to 8 carbon atoms, and containing zero or one or more double or triple bonds, each of which 1 to 8 carbon atoms is unsubstituted or substituted with one or more substituent(s) independently selected from oxo, hydroxy, halogen, amino, cyano, nitro, haloalkyl, haloalkoxy, -O(C₁₋₄alkyl), -NH(C₁₋₄alkyl), -N(C₁₋₄alkyl)(C₁₋₄alkyl), -NHC(O)(C₁₋₄alkyl), -N(C₁₋₄alkyl)C(O)(C₁₋₄alkyl), -NHS(O)_n(C₁₋₄alkyl), -S(O)_n(C₁₋


$\text{C}_1\text{-}_4\text{alkyl}$), $-\text{S}(\text{O})_n\text{NH}(\text{C}_1\text{-}_4\text{alkyl})$, $-\text{S}(\text{O})_n\text{N}(\text{C}_1\text{-}_4\text{alkyl})_3(\text{C}_1\text{-}_4\text{alkyl})_4$ where $\text{C}_1\text{-}_4\text{alkyl}_3$ and $\text{C}_1\text{-}_4\text{alkyl}_4$ are optionally joined to form a saturated heterocyclic ring [heterocycle] consisting of from 5 to 8 ring atoms and containing 1, 2, or 3 heteroatoms independently selected from N, O, and S, and Y';

C¹ Y and Y' are independently selected at each occurrence from 3- to 8-membered carbocyclic or heterocyclic groups which are saturated, unsaturated, or aromatic, which may be further substituted with one or more substituents independently selected from halogen, oxo, hydroxy, amino, nitro, cyano, $\text{C}_1\text{-}_4\text{alkyl}$, $\text{C}_1\text{-}_4\text{alkoxy}$, halo($\text{C}_1\text{-}_4$)alkyl, halo($\text{C}_1\text{-}_4$)alkoxy, mono- or di($\text{C}_1\text{-}_4$)alkylamino, and $\text{C}_1\text{-}_4\text{alkylthio}$;


wherein said 3- to 8-membered heterocyclic groups contain one or more heteroatom(s) independently selected from N, O, and S; and

n is independently chosen at each occurrence from 0, 1, and 2.


~~27~~₃₂. (Previously Amended) A compound of the Formula A, Formula B, Formula C, Formula D, Formula E, or Formula F:




Formula A



Formula B



Formula C



Formula D



A represents NH or O;

(a) selected from the group consisting of hydrogen, halogen, cyano, nitro, halo(C₁₋₆)alkyl, halo(C₁₋₆)alkoxy, hydroxy, amino, C₁₋₆alkyl substituted with 0-2 R₆, C₂₋₆alkenyl substituted with 0-2 R₆; C₂₋₆alkynyl substituted with 0-2 R₆; C₁₋₆alkoxy substituted with 0-2 R₆, -NH(C₁₋₆alkyl) substituted with 0-2 R₆, -N(C₁₋

₆alkyl)(C₁₋₆alkyl) where each C₁₋₆alkyl is independently substituted with 0-2 R₆, -XR₇, and Y; or

- (b) joined to a R₃ or R₄ not attached to the same carbon to form an aryl ring substituted with 0-3 R₆, a saturated or partially unsaturated carbocyclic ring of from 5 to 8 members, which carbocyclic ring is substituted with 0-2 R₆, or a saturated, partially unsaturated, or aromatic heterocyclic ring of from 5 to 8 members, which heterocyclic ring is substituted with 0-2 R₆ and contains 1, 2, or 3 heteroatoms independently selected from N, O, and S;

C1
R₅ represents from 1 to 3 substituents independently selected at each occurrence from the group consisting of halogen, cyano, nitro, halo(C₁₋₆)alkyl, halo(C₁₋₆)alkoxy, hydroxy, amino, C₁₋₆alkyl substituted with 0-2 R₆, C₂₋₆alkenyl substituted with 0-2 R₆, C₂₋₆alkynyl substituted with 0-2 R₆, C₁₋₆alkoxy, -NH(C₁₋₆alkyl) substituted with 0-2 R₆, -N(C₁₋₆alkyl)(C₁₋₆alkyl) where each C₁₋₆alkyl is independently substituted with 0-2 R₆, -XR₇, and Y;

R₉ represents from 1 to 3 substituents independently selected at each occurrence from the group consisting of halogen, cyano, nitro, halo(C₁₋₆)alkyl, halo(C₁₋

C

6)alkoxy, hydroxy, amino, C₁₋₆alkyl substituted with 0-2 R₆, C₂₋₆alkenyl substituted with 0-2 R₆, C₂₋₆alkynyl substituted with 0-2 R₆, C₁₋₆alkoxy substituted with 0-2 R₆, and Y;

C1
R₆ is independently selected at each occurrence from the group consisting of halogen, hydroxy, cyano, C₁₋₄alkyl, C₁₋₄alkoxy, -S(O)_n(C₁₋₄alkyl), halo(C₁₋₄)alkyl, halo(C₁₋₄)alkoxy, CO(C₁₋₄alkyl), CONH(C₁₋₄alkyl), CON(C₁₋₄alkyl₁)(C₁₋₄alkyl₂) where alkyl₁ and alkyl₂ may be joined to form a saturated heterocyclic ring [heterocycle] of from 5 to 8 ring atoms and containing 1, 2, or 3 heteroatoms independently selected from N, O, and S, -XR₇, and Y;

X is independently selected at each occurrence from the group consisting of -CH₂-, -CHR₈-, -O-, -S(O)_n-, -NH-, -NR₈-, -C(=O)-, -C(=O)O-, -C(=O)NH-, -C(=O)NR₈-, -S(O)_nNH-, -S(O)_nNR₈-, NHC(=O)-, -NR₈C(=O)-, -NHS(O)_n-, and -NR₈S(O)_n-;

R₇ and R₈ are independently selected at each occurrence from hydrogen, and straight, branched, and cyclic alkyl groups, and (cycloalkyl)alkyl groups, said straight, branched, and cyclic alkyl groups, and (cycloalkyl)alkyl groups consisting of 1 to 8 carbon

C1
atoms, and containing zero or one or more double or triple bonds, each of which 1 to 8 carbon atoms is unsubstituted or substituted with one or more substituent(s) independently selected from oxo, hydroxy, halogen, amino, cyano, nitro, haloalkyl, haloalkoxy, $-O(C_{1-4}alkyl)$, $-NH(C_{1-4}alkyl)$, $-N(C_{1-4}alkyl)(C_{1-4}alkyl)$, $-NHC(O)(C_{1-4}alkyl)$, $-N(C_{1-4}alkyl)C(O)(C_{1-4}alkyl)$, $-NHS(O)_n(C_{1-4}alkyl)$, $-S(O)_n(C_{1-4}alkyl)$, $-S(O)_nNH(C_{1-4}alkyl)$, $-S(O)_nN(C_{1-4}alkyl)_3(C_{1-4}alkyl_4)$ where $C_{1-4}alkyl_3$ and $C_{1-4}alkyl_4$ are optionally joined to form a saturated heterocyclic ring [heterocycle] consisting of from 5 to 8 ring atoms and containing 1, 2, or 3 heteroatoms independently selected from N, O, and S, and Y';

Y and Y' are independently selected at each occurrence from 3- to 8-membered carbocyclic or heterocyclic groups which are saturated, unsaturated, or aromatic, which may be further substituted with one or more substituents independently selected from halogen, oxo, hydroxy, amino, nitro, cyano, $C_{1-4}alkyl$, $C_{1-4}alkoxy$, $halo(C_{1-4})alkyl$, $halo(C_{1-4})alkoxy$, mono- or di($C_{1-4}alkylamino$), and $C_{1-4}alkylthio$;

wherein said 3- to 8-membered heterocyclic groups contain one or more heteroatom(s) independently selected from N, O, and S; and
n is independently chosen at each occurrence from 0, 1, and 2.

²⁸
~~33~~. (Original) A compound or salt according to Claim
~~27~~ ²⁸ ~~32~~, wherein A represents NH.

²⁹
~~30~~
²⁷ ~~28~~ ²⁹ ~~34~~. (Original) A compound or salt according to Claim
~~32~~, wherein:

A represents NH; and

R₃ and R₄ are independently chosen at each occurrence from the group consisting of hydrogen, halogen, cyano, nitro, halo(C₁₋₆)alkyl, halo(C₁₋₆)alkoxy, hydroxy, amino, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy substituted with 0-2 R₆, - NH(C₁₋₆alkyl), and -N(C₁₋₆alkyl)(C₁₋₆alkyl).

³⁰
²⁷ ~~28~~ ³⁰ ~~35~~. (Original) A compound or salt according to Claim
~~32~~, wherein:

A represents NH;

R₃ represents hydrogen; and

R₄ is independently chosen at each occurrence from hydrogen and C₁₋₆ alkyl.

³¹
~~27~~ 36. (Original) A compound or salt according to Claim ~~32~~, wherein:

A represents NH;

R₃ represents hydrogen; and

R₄ is independently chosen at each occurrence from hydrogen and methyl.

C1 ³⁹
~~37~~ 37. (Previously Amended) A compound or salt according to Claim ~~32~~, wherein:

A represents NH;

R₃ represents hydrogen;

R₄ is independently chosen at each occurrence from hydrogen and methyl; and


R₅ represents from 1 to 3 substituents independently selected at each occurrence from the group consisting of halogen, cyano, nitro, halo(C₁₋₆)alkyl, halo(C₁₋₆)alkoxy, hydroxy, amino, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, -NH(C₁₋₆alkyl), -N(C₁₋₆alkyl)(C₁₋₆alkyl), and C₃₋₈ cycloalkyl; and

C

R₉ represents from 1 to 3 substituents independently selected at each occurrence from the group consisting of halogen, nitro, halo(C₁₋₆)alkyl, halo(C₁₋₆)alkoxy, hydroxy, amino, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, and C₃₋₈ cycloalkyl.

33
~~34~~

38. (Previously Amended) A compound or salt of the Formula A-1



Formula A-1

wherein

R₄ is hydrogen or methyl;

R₅ and R₉ are independently selected from the group consisting of halogen, cyano, nitro, halo(C₁₋₆)alkyl, halo(C₁₋₆)alkoxy, hydroxy, amino, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, -NH(C₁₋₆alkyl), -N(C₁₋₆alkyl)(C₁₋₆alkyl), and C₃₋₈ cycloalkyl; and

R_{5B} and R_{9B} each represent from 0 to 2 substituents independently selected at each occurrence from hydrogen, halogen, cyano, nitro, halo(C₁₋₂)alkyl,

halo(C₁₋₂)alkoxy, hydroxy, amino, C₁₋₃alkyl, C₁₋₃alkoxy, -NH(C₁₋₃alkyl), and -N(C₁₋₆alkyl)(C₁₋₆alkyl).


33
~~38~~
39. (Original) A compound or salt according to Claim 38, wherein:

R₅ is C₃₋₆ alkyl; C₃₋₆ alkoxy; halo(C₁₋₃)alkyl, halo(C₁₋₃)alkoxy, or C₃₋₈ cycloalkyl;

R₉ is chloro or trifluoromethyl; and

R_{5B} and R_{9B} are hydrogen.

C1
~~36~~
40. (Previously Amended) A compound or salt of Formula B-1:



Formula B-1

wherein

R₄ is hydrogen or methyl;

R₅ and R₉ are independently selected from the group consisting of halogen, cyano, nitro, halo(C₁₋₆)alkyl, halo(C₁₋₆)alkoxy, hydroxy, amino, C₁₋₆alkyl, C₂₋₆alkenyl,

C₂₋₆alkynyl, C₁₋₆alkoxy, -NH(C₁₋₆alkyl), -N(C₁₋₆alkyl)(C₁₋₆alkyl), and C₃₋₈ cycloalkyl; and

R_{5B} and R_{9B} each represent from 0 to 2 substituents independently selected at each occurrence from hydrogen, halogen, cyano, nitro, halo(C₁₋₂)alkyl, halo(C₁₋₂)alkoxy, hydroxy, amino, C₁₋₃alkyl, C₁₋₃alkoxy, -NH(C₁₋₃alkyl), and -N(C₁₋₆alkyl)(C₁₋₆alkyl).


C1 ~~36~~
~~41~~. (Original) A compound or salt according to Claim ~~36~~
~~40~~, wherein:

R₅ is C₃₋₆ alkyl; C₃₋₆ alkoxy; halo(C₁₋₃)alkyl, halo(C₁₋₃)alkoxy, or C₃₋₈ cycloalkyl;

R₉ is chloro or trifluoromethyl; and

R_{5B} and R_{9B} are hydrogen.

~~38~~
~~42~~. (Previously Amended) A compound or salt of Formula C-1:



Formula C-1

wherein:

R₄ is hydrogen or methyl;

R₅ and R₉ are independently selected from the group consisting of halogen, cyano, nitro, halo(C₁₋₆)alkyl, halo(C₁₋₆)alkoxy, hydroxy, amino, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, -NH(C₁₋₆alkyl), -N(C₁₋₆alkyl)(C₁₋₆alkyl), and C₃₋₈ cycloalkyl; and

C1
R_{5B} and R_{9B} each represent from 0 to 2 substituents independently selected at each occurrence from hydrogen, halogen, cyano, nitro, halo(C₁₋₂)alkyl, halo(C₁₋₂)alkoxy, hydroxy, amino, C₁₋₃alkyl, C₁₋₃alkoxy, -NH(C₁₋₃alkyl), and -N(C₁₋₆alkyl)(C₁₋₆alkyl).

37
~~38~~
43. (Original) A compound or salt according to Claim ~~42~~, wherein:

R₅ is C₃₋₆ alkyl; C₃₋₆ alkoxy; halo(C₁₋₃)alkyl, halo(C₁₋₃)alkoxy, or C₃₋₈ cycloalkyl;


R₉ is chloro or trifluoromethyl; and

R_{5B} and R_{9B} are hydrogen.

39
~~40~~
44. (Previously Amended) A compound or salt according to Claim ~~37~~ of Formula D-1:

32

C



Formula D-1

wherein:

C1
R₅ is selected from the group consisting of halogen, cyano, nitro, halo(C₁₋₆)alkyl, halo(C₁₋₆)alkoxy, hydroxy, amino, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, -NH(C₁₋₆alkyl), -N(C₁₋₆alkyl)(C₁₋₆alkyl), and C₃₋₈ cycloalkyl;

R₉ is selected from the group consisting of halogen, cyano, nitro, halo(C₁₋₆)alkyl, halo(C₁₋₆)alkoxy, hydroxy, amino, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, and C₃₋₈ cycloalkyl; and

R_{5B} and R_{9B} each represent from 0 to 2 substituents independently selected at each occurrence from hydrogen, halogen, cyano, nitro, halo(C₁₋₂)alkyl, halo(C₁₋₂)alkoxy, hydroxy, amino, C₁₋₃alkyl, C₁₋₃alkoxy, -NH(C₁₋₃alkyl), and -N(C₁₋₆alkyl)(C₁₋₆alkyl).


39
40
44, wherein:
45. (Original) A compound or salt according to Claim

R₅ is C₃₋₆ alkyl; C₃₋₆ alkoxy; halo(C₁₋₃)alkyl, halo(C₁₋₃)alkoxy, or C₃₋₈ cycloalkyl;

R₉ is chloro or trifluoromethyl; and

R_{5B} and R_{9B} are hydrogen.

~~41~~
~~46~~. (Previously Amended) A compound or salt of
Formula E-1:



Formula E-1

wherein:

R₄ is hydrogen or methyl;

R₅ and R₉ are independently selected from the group consisting of halogen, cyano, nitro, halo(C₁₋₆)alkyl, halo(C₁₋₆)alkoxy, hydroxy, amino, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, -NH(C₁₋₆alkyl), -N(C₁₋₆alkyl)(C₁₋₆alkyl), and C₃₋₈ cycloalkyl; and

R_{5B} and R_{9B} each represent from 0 to 2 substituents independently selected at each occurrence from hydrogen, halogen, cyano, nitro, halo(C₁₋₂)alkyl,

halo(C₁₋₂)alkoxy, hydroxy, amino, C₁₋₃alkyl, C₁₋₃alkoxy, -NH(C₁₋₃alkyl), and -N(C₁₋₆alkyl)(C₁₋₆alkyl).


⁴⁹
~~47~~. (Original) A compound or salt according to Claim ⁴¹
~~46~~, wherein:

R₅ is C₃₋₆ alkyl; C₃₋₆ alkoxy; halo(C₁₋₃)alkyl, halo(C₁₋₃)alkoxy, or C₃₋₈ cycloalkyl;

R₉ is chloro or trifluoromethyl; and

R_{5B} and R_{9B} are hydrogen.

⁴³
~~44~~
~~48~~. (Previously Amended) A compound of salt of Formula F-1:



Formula F-1

wherein:

R₄ is hydrogen or methyl;

R₅ and R₉ are independently selected from the group consisting of halogen, cyano, nitro, halo(C₁₋₆)alkyl, halo(C₁₋₆)alkoxy, hydroxy, amino, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, -NH(C₁₋₆alkyl), -N(C₁₋₆alkyl)(C₁₋₆alkyl), and C₃₋₈ cycloalkyl; and

R_{5B} and R_{9B} each represent from 0 to 2 substituents independently selected at each occurrence from hydrogen, halogen, cyano, nitro, halo(C₁₋₂)alkyl, halo(C₁₋₂)alkoxy, hydroxy, amino, C₁₋₃alkyl, C₁₋₃alkoxy, -NH(C₁₋₃alkyl), and -N(C₁₋₆alkyl)(C₁₋₆alkyl).


~~44~~
~~42~~
~~41~~ 49. (Original) A compound or salt according to Claim
47, wherein:

C1
R₅ is C₃₋₆ alkyl; C₃₋₆ alkoxy; halo(C₁₋₃)alkyl, halo(C₁₋₃)alkoxy, or C₃₋₈ cycloalkyl;

R₉ is chloro or trifluoromethyl; and

R_{5B} and R_{9B} are hydrogen.

~~45~~
50. (Previously Amended) A compound of the Formula:



or a pharmaceutically acceptable salt thereof, wherein:

A is absent or is selected from the group consisting of O, S, NR_A, CR_BR_{B'}, NR_ACR_BR_{B'}, CR_BR_{B'}NR_A, -CR_A=CR_B-, and C₃H₄; where R_A, R_B, and R_{B'} are independently selected at each occurrence from hydrogen and C₁₋₆ alkyl;

each R₃ and R₄ is independently

(a) selected from the group consisting of hydrogen, halogen, cyano, nitro, halo(C₁₋₆)alkyl, halo(C₁₋₆)alkoxy, hydroxy, amino, C₁₋₆alkyl substituted with 0-2 R₆, C₂₋₆alkenyl substituted with 0-2 R₆; C₂₋₆alkynyl substituted with 0-2 R₆; C₁₋₆alkoxy substituted with 0-2 R₆, -NH(C₁₋₆alkyl) substituted with 0-2 R₆, -N(C₁₋₆alkyl)(C₁₋₆alkyl) where each C₁₋₆alkyl is independently substituted with 0-2 R₆, -XR₇, and Y; or

C1
(b) joined to a R₃ or R₄ not attached to the same carbon to form an aryl ring substituted with 0-3 R₆, a saturated or partially unsaturated carbocyclic ring of from 5 to 8 members, which carbocyclic ring is substituted with 0-2 R₆, or a saturated, partially unsaturated, or aromatic heterocyclic ring of from 5 to 8 members, which heterocyclic ring is substituted with 0-2 R₆ and contains 1, 2, or 3 heteroatoms independently selected from N, O, and S;

R₅ is selected from the group consisting of bromo, fluoro, iodo, halo(C₁₋₆)alkyl, halo(C₃₋₆)alkoxy, C₃₋₆alkyl substituted with 0-3 R₆, C₂₋₆alkenyl substituted with 0-3 R₆, C₂₋₆alkynyl substituted with 0-3 R₆, C₃₋₆alkoxy, (C₃₋₈cycloalkyl)C₁₋₄alkyl, -NH(C₁₋₆alkyl) substituted

C

with 0-2 R_6 , $-N(C_{1-6}alkyl)(C_{1-6}alkyl)$ where each $C_{1-6}alkyl$ is substituted with 0-2 R_6 , Y, $-(C=O)Y$, $-(CH_2)Y$, and $-(CH(CN))Y$;

C) R_9 is selected from the group consisting of halogen, cyano, $-N(SO_2C_{1-6}alkyl)(SO_2C_{1-6}alkyl)$, $-SO_2NH_2$, $halo(C_{1-6})alkyl$, $halo(C_{1-6})alkoxy$, $C_{1-6}alkyl$ substituted with 0-2 R_6 , $C_{2-6}alkenyl$ substituted with 0-2 R_6 , $C_{2-6}alkynyl$ substituted with 0-2 R_6 , and $C_{1-6}alkoxy$ substituted with 0-2 R_6 ;

R_{5B} represents from 0 to 2 substituents independently selected at each occurrence from the group consisting of

(a) halogen, cyano, nitro, $halo(C_{1-6})alkyl$, $halo(C_{1-6})alkoxy$, hydroxy, amino, $C_{1-6}alkyl$ substituted with 0-2 R_6 , $(C_{3-8}cycloalkyl)C_{1-4}alkyl$ substituted with 0-2 R_6 , $C_{2-6}alkenyl$ substituted with 0-2 R_6 , $C_{2-6}alkynyl$ substituted with 0-2 R_6 , $C_{1-6}alkoxy$, $-NH(C_{1-6}alkyl)$ substituted with 0-2 R_6 , $-N(C_{1-6}alkyl)(C_{1-6}alkyl)$ where each $C_{1-6}alkyl$ is independently substituted with 0-2 R_6 , and Y; and

(b) groups that are joined to R_5 to form a $C_{3-8}cycloalkyl$ group or a saturated heterocyclic ring or partially unsaturated heterocycle, each of which is optionally

substituted by from 1 to 5 substituents independently chosen from cyano, halogen, hydroxy, C₁₋₄alkyl, C₁₋₄alkoxy, -NH(C₁₋₄alkyl), -N(C₁₋₄alkyl)(C₁₋₄alkyl), halo(C₁₋₄)alkyl, and halo(C₁₋₄)alkoxy, wherein the saturated heterocyclic ring or partially unsaturated heterocycle contains from 4 to 8 ring atoms of which 1, 2, or 3 are heteroatoms independently selected from N, O, and S;

C1
R_{9B} represents from 0 to 2 substituents independently selected at each occurrence from halogen, cyano, nitro, halo(C₁₋₆)alkyl, halo(C₁₋₆)alkoxy, hydroxy, amino, C₁₋₆alkyl substituted with 0-2 R₆, (C₃₋₈cycloalkyl)C₁₋₄alkyl substituted with 0-2 R₆, C₂₋₆alkenyl substituted with 0-2 R₆, C₂₋₆alkynyl substituted with 0-2 R₆, C₁₋₆alkoxy substituted with 0-2 R₆, and Y;

R₆ is independently selected at each occurrence from the group consisting of cyano, halogen, hydroxy, C₁₋₄alkyl, C₁₋₄alkoxy, -S(O)_n(C₁₋₄alkyl), halo(C₁₋₄)alkyl, halo(C₁₋₄)alkoxy, CO(C₁₋₄alkyl), CONH(C₁₋₄alkyl), CON(C₁₋₄alkyl₁)(C₁₋₄alkyl₂) where alkyl₁ and alkyl₂ may be joined to form a saturated heterocyclic ring [heterocycle] of from 5 to 8 ring atoms and containing 1, 2, or 3

heteroatoms independently selected from N, O, and S, -
XR₇, and Y;

C1 X is independently selected at each occurrence from the
group consisting of -CH₂-, -CHR₈-, -O-, -S(O)_n-, -NH-,
-NR₈-, -C(=O)-, -C(=O)NH-, -C(=O)NR₈-, -S(O)_nNH-,
-S(O)_nNR₈-, NHC(=O)-, -NR₈C(=O)-, -NHS(O)_n-, and
-NR₈S(O)_n-;

R₇ and R₈ are independently selected at each occurrence from
hydrogen, and straight, branched, and cyclic alkyl
groups, and (cycloalkyl)alkyl groups, said straight,
branched, and cyclic alkyl groups, and
(cycloalkyl)alkyl groups consisting of 1 to 8 carbon
atoms, and containing zero or one or more double or
triple bonds, each of which 1 to 8 carbon atoms may be
further substituted with one or more substituent(s)
independently selected from oxo, hydroxy, halogen,
amino, cyano, nitro, haloalkyl, haloalkoxy, -O(C₁₋₄
alkyl), NH(C₁₋₄alkyl), -N(C₁₋₄alkyl)(C₁₋₄alkyl),
-NHC(O)(C₁₋₄alkyl), -N(C₁₋₄alkyl)C(O)(C₁₋₄alkyl),
-NHS(O)_n(C₁₋₄alkyl), -S(O)_n(C₁₋₄alkyl), -S(O)_nNH(C₁₋₄
alkyl), -S(O)_nN(C₁₋₄alkyl)₃(C₁₋₄alkyl)₄ where C₁₋₄alkyl₃
and C₁₋₄alkyl₄ are optionally joined to form a saturated
heterocyclic ring [heterocycle] consisting of from 5

to 8 ring atoms and containing 1, 2, or 3 heteroatoms independently selected from N, O, and S, and Y';

C1
Y and Y' are independently selected at each occurrence from 3- to 8-membered carbocyclic or heterocyclic groups which are saturated, unsaturated, or aromatic, which may be further substituted with one or more substituents independently selected from halogen, oxo, hydroxy, amino, nitro, cyano, C₁₋₄alkyl, C₁₋₄alkoxy, halo(C₁₋₄)alkyl, halo(C₁₋₄)alkoxy, mono- or di(C₁₋₄)alkylamino, and C₁₋₄alkylthio; wherein said 3- to 8-membered heterocyclic groups contain one or more heteroatom(s) independently selected from N, O, and S; and

n is independently chosen at each occurrence from 0, 1, and 2.

~~46~~
~~51~~. (Original) A compound or salt according to Claim ~~46~~
~~50~~, wherein:

A is O or NR_A, wherein R_A is hydrogen or methyl.

~~47~~
~~52~~. (Original) A compound or salt according to Claim ~~46~~
~~50~~, wherein:

A is O or NR_A, wherein R_A is hydrogen or methyl; and

R₃ and R₄ are independently chosen at each occurrence from the group consisting of hydrogen, halogen, cyano, nitro, halo(C₁₋₆)alkyl, halo(C₁₋₆)alkoxy, hydroxy, amino, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, -NH(C₁₋₆alkyl), and -N(C₁₋₆alkyl)(C₁₋₆alkyl).

⁴⁸
~~45~~ 53. (Original) A compound or salt according to Claim ~~50~~, wherein:

A is O or NR_A, wherein R_A is hydrogen or methyl;

C1
R₃ is hydrogen; and

R₄ is independently chosen at each occurrence from the group consisting of hydrogen, halogen, cyano, nitro, halo(C₁₋₆)alkyl, halo(C₁₋₆)alkoxy, hydroxy, amino, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, -NH(C₁₋₆alkyl), and -N(C₁₋₆alkyl)(C₁₋₆alkyl).

⁴⁹
~~45~~ 54. (Original) A compound or salt according to Claim ~~50~~, wherein:

A is O or NR_A, wherein R_A is hydrogen or methyl;

R₃ is hydrogen; and

R₄ is independently chosen at each occurrence from hydrogen and C₁₋₆alkyl.

50
45
50, wherein:

55. (Original) A compound or salt according to Claim

A is NR_A , wherein R_A is hydrogen or methyl;

R_3 is hydrogen; and

R_4 is independently chosen at each occurrence from hydrogen, halo(C_{1-3})alkyl, and C_{1-6} alkyl.

51
45
50, wherein:

56. (Original) A compound or salt according to Claim


A is NR_A , wherein R_A is hydrogen or methyl;

R_3 is hydrogen; and

R_4 is independently chosen at each occurrence from hydrogen and C_{1-4} alkyl.

52
45
50 of the Formula:


57. (Original) A compound or salt according to Claim



wherein:

R_4 is independently chosen at each occurrence from hydrogen and C_{1-4} alkyl.

53
58. (Original) A compound or salt according to Claim
59 of the formula:



wherein

C1
R_{5B} and R_{9B} are independently chosen from hydrogen, halogen, cyano, nitro, halo(C₁₋₂)alkyl, halo(C₁₋₂)alkoxy, amino, C₁₋₄alkyl, and C₁₋₂alkoxy; and

R₁₀ is independently chosen at each occurrence from hydrogen, halogen, and C₁₋₄ alkyl.

54
59. (Previously Amended) A compound or salt
53 according to Claim 58 wherein:

R₉ is selected from the group consisting of halogen, cyano, -N(SO₂CH₃)₂, -SO₂NH₂, halo(C₁₋₃)alkyl, and C₁₋₃alkoxy.

55
60. (Original) A compound or salt according to Claim
59, wherein:

R_{5B} and R_{9B} are independently chosen from hydrogen, halogen, cyano, nitro, halo(C₁₋₂)alkyl, halo(C₁₋₂)alkoxy, amino, C₁₋₄alkyl, and C₁₋₂alkoxy.

~~56~~
~~51~~. (Original) A compound or salt according to Claim ~~52~~
~~51~~, wherein:

C1
R_{5B} represents 0 or 1 substituents chosen from halogen, cyano, nitro, halo(C₁₋₂)alkyl, halo(C₁₋₂)alkoxy, amino, C₁₋₄alkyl, and C₁₋₂alkoxy; and

R_{9B} represents 0 or 1 substituents chosen from halogen, cyano, nitro, halo(C₁₋₂)alkyl, and C₁₋₂alkyl, and C₁₋₂alkoxy.

~~57~~
~~52~~. (Previously Amended) A compound or salt according to Claim ~~51~~, wherein:

R₉ is selected from the group consisting of halogen, cyano, -N(SO₂CH₃)₂, -SO₂NH₂, halo(C₁₋₃)alkyl, and C₁₋₃alkoxy;

R_{5B} represents 0 or 1 substituents chosen from halogen, cyano, nitro, halo(C₁₋₂)alkyl, halo(C₁₋₂)alkoxy, amino, C₁₋₄alkyl, and C₁₋₂alkoxy; and

R_{9B} represents 0 or 1 substituents chosen from halogen, cyano, nitro, halo(C₁₋₂)alkyl, [and] C₁₋₂alkyl, and C₁₋₂alkoxy.

⁵⁸
~~63~~. (Previously Amended) A compound or salt according
to Claim ⁵²~~57~~, wherein:

R₅ is selected from the group consisting of bromo, fluoro, iodo, halo(C₁₋₆)alkyl, halo(C₃₋₆)alkoxy, C₃₋₆alkyl substituted with 0-3 R₆, C₂₋₆alkenyl substituted with 0-3 R₆, Y, -(C=O)Y, -(CH₂)Y, and -(CH(CN))Y;

C1
R₉ is selected from the group consisting of halogen, cyano, -N(SO₂CH₃)₂, -SO₂NH₂, halo(C₁₋₂)alkyl, C₁₋₃alkoxy;

R_{5B} represents 0 or 1 substituents chosen from halogen, cyano, nitro, halo(C₁₋₂)alkyl, halo(C₁₋₂)alkoxy, amino, C₁₋₄alkyl, and C₁₋₂alkoxy; and

R_{9B} represents 0 or 1 substituents chosen from halogen, cyano, nitro, halo(C₁₋₂)alkyl, C₁₋₂alkyl, and C₁₋₂alkoxy.

⁵⁹
~~64~~. (Original) A compound or salt according to Claim
⁵⁸
~~63~~, wherein:

R₆ is independently selected at each occurrence from the group consisting of cyano, halogen, hydroxy, C₁₋₄alkyl, C₁₋₄alkoxy, -NH(C₁₋₄alkyl), and -N(C₁₋₄alkyl)(C₁₋₄alkyl) and Y; and

Y is independently selected at each occurrence from C₃₋₈ cycloalkyl, piperidinyl, piperazinyl,

tetrahydropyranyl, dihydropyranyl, morpholinyl, thiomorpholinyl, phenyl, pyridyl, pyrazinyl, pyrimidinyl, thiazolyl, thienyl, and imidazolyl, each of which may be further substituted with one or more substituents independently selected from halogen, oxo, hydroxy, amino, nitro, cyano, C₁₋₄alkyl, C₁₋₄alkoxy, halo(C₁₋₄)alkyl, halo(C₁₋₄)alkoxy, mono- or di(C₁₋₄)alkylamino, and C₁₋₄alkylthio.

C1
~~58~~⁶⁰
~~63~~. (Original) A compound or salt according to Claim ~~50~~⁴⁵, wherein:

R₉ is cyano, trifluoromethyl, chloro, or iodo; and

R_{9B} is hydrogen.

~~66~~⁶⁷. (Original) A compound according to Claim ~~50~~⁴⁵, which is

N-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl)piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

~~67~~⁶⁹. (Original) A compound according to Claim ~~50~~⁴⁵, which is (2R)-4-(3-chloropyridin-2-yl)-N-(4-cyclohexylphenyl)-2-

methylnpiperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

~~63~~
~~68~~. (Original) A compound according to Claim ~~50~~,⁴⁵ which is (2R)-4-(3-chloropyridin-2-yl)-2-methyl-N-[4-(trifluoromethyl) phenyl]piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

~~64~~
~~69~~. (Original) A compound according to Claim ~~50~~,⁴⁵ which is (2R)-N-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl)-2-methylpiperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

~~65~~
~~70~~. (Original) A compound according to Claim ~~50~~,⁴⁵ which is (2R)-4-(3-chloropyridin-2-yl)-N-(4-isopropylphenyl)-2-methylpiperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

~~66~~
~~71~~. (Original) A compound according to Claim ~~50~~,⁴⁵ which is (2S)-4-(3-chloropyridin-2-yl)-N-(4-trifluoromethylphenyl)-2-methylpiperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

⁶⁷
~~72~~. (Original) A compound according to Claim ⁴⁵~~50~~,
which is (2S)-N-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl)-2-methylpiperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

⁶⁸
~~73~~. (Original) A compound according to Claim ⁴⁵~~50~~,
which is (2S)-4-(3-chloropyridin-2-yl)-N-(4-isopropylphenyl)-2-methylpiperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

C1 ⁶⁹
~~74~~. (Original) A compound according to Claim ⁴⁵~~50~~,
which is (2R)-4-(3-chloropyridin-2-yl)-2-methyl-N-(4-piperidin-1-ylphenyl)piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

⁷⁰
~~75~~. (Original) A compound according to Claim ⁴⁵~~50~~,
which is (2R)-4-(3-chloropyridin-2-yl)-N-[2-fluoro-4-(trifluoromethyl)phenyl]-2-methylpiperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

⁷¹
~~76~~. (Original) A compound according to Claim ⁴⁵~~50~~,
which is (2R)-2-methyl-N-[4-(trifluoromethyl)phenyl]-4-[3-

(trifluoromethyl)pyridin-2-yl]piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

~~77~~⁷². (Original) A compound according to Claim ~~50~~⁴⁵, which is (2R)-N-(4-tert-butylphenyl)-2-methyl-4-[3-(trifluoromethyl)pyridin-2-yl]piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

~~78~~⁷³. (Original) A compound according to Claim ~~50~~⁴⁵, which is (2R)-N-(4-isopropylphenyl)-2-methyl-4-[3-(trifluoromethyl)pyridin-2-yl]piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

~~79~~⁷⁴. (Original) A compound according to Claim ~~50~~⁴⁵, which is 4-(3-chloropyridin-2-yl)-2,6-dimethyl-N-[4-(trifluoromethyl)phenyl]piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

~~80~~⁷⁵. (Original) A compound according to Claim ~~50~~⁴⁵, which is N-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl)-2,6-dimethylpiperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

~~76~~
81. (Original) A compound according to Claim ~~50~~⁴⁵,
which is 4-(3-chloropyridin-2-yl)-N-(4-isopropylphenyl)-
2,6-dimethylpiperazine-1-carboxamide, or a pharmaceutically
acceptable salt thereof.

~~77~~
82. (Original) A compound according to Claim ~~50~~⁴⁵,
which is (2R)-N-(4-cyclohexylphenyl)-2-methyl-4-[3-
(trifluoromethyl)pyridin-2-yl]piperazine-1-carboxamide, or
a pharmaceutically acceptable salt thereof.

C1 ~~78~~
83. (Original) A compound according to Claim ~~50~~⁴⁵,
which is 4-(3-chloropyridin-2-yl)-N-(4-cyclohexylphenyl)-
2,6-dimethylpiperazine-1-carboxamide, or a pharmaceutically
acceptable salt thereof.

~~79~~
84. (Original) A compound according to Claim ~~50~~⁴⁵,
which is (2R)-4-(3-chloropyridin-2-yl)-N-(4-
cyclopentylphenyl)-2-methylpiperazine-1-carboxamide, or a
pharmaceutically acceptable salt thereof.

~~80~~
85. (Original) A compound according to Claim ~~50~~⁴⁵,
which is (2R)-N-(4-cyclopentylphenyl)-2-methyl-4-[3-

(trifluoromethyl)pyridin-2-yl]piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

86. (Cancelled)

87. (Cancelled)

~~88~~⁸¹

~~88~~. (Original) A compound according to Claim ~~50~~⁴⁵, which is (2R)-N-(4-tert-butylphenyl)-4-(3-methoxypyridin-2-yl)-2-methylpiperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

~~89~~⁸²

~~89~~. (Original) A compound according to Claim ~~50~~⁴⁵, which is (2R)-4-(3-methoxypyridin-2-yl)-2-methyl-N-[4-(trifluoromethyl)phenyl] piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

~~90~~⁸³

~~90~~. (Original) A compound according to Claim ~~50~~⁴⁵, which is (2R)-N-(4-cyclohexylphenyl)-4-(3-methoxypyridin-2-yl)-2-methylpiperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

~~84~~
91. (Original) A compound according to Claim ~~50~~⁴⁵,
which is (2R)-4-(3-chloropyridin-2-yl)-N-[4-(3,6-dihydro-
2H-pyran-4-yl)phenyl]-2-methylpiperazine-1-carboxamide, or
a pharmaceutically acceptable salt thereof.

~~85~~
92. (Original) A compound according to Claim ~~50~~⁴⁵,
which is (2R)-4-(3-chloropyridin-2-yl)-2-methyl-N-(4-
tetrahydro-2H-pyran-4-ylphenyl)piperazine-1-carboxamide, or
a pharmaceutically acceptable salt thereof.

C1 ~~86~~
93. (Original) A compound according to Claim ~~50~~⁴⁵,
which is (2R)-4-(3-chloropyridin-2-yl)-N-[4-(4-
hydroxytetrahydro-2H-pyran-4-yl)phenyl]-2-methylpiperazine-
1-carboxamide, or a pharmaceutically acceptable salt
thereof.

~~87~~
94. (Original) A compound according to Claim ~~50~~⁴⁵,
which is (2R)-N-[4-(4-hydroxytetrahydro-2H-pyran-4-
yl)phenyl]-2-methyl-4-[3-(trifluoromethyl)pyridin-2-
yl]piperazine-1-carboxamide, or a pharmaceutically
acceptable salt thereof.

⁸⁸
~~95~~. (Original) A compound according to Claim ~~50~~,⁴⁵
which is (2R)-4-(3-chloropyridin-2-yl)-2-methyl-N-[4-(2-methyl-1,3-thiazol-4-yl)phenyl]piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

⁸⁹
~~96~~. (Original) A compound according to Claim ~~50~~,⁴⁵
which is (2R)-4-(3-chloropyridin-2-yl)-N-[4-(2-ethyl-1,3-thiazol-4-yl)phenyl]-2-methylpiperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

C1 ⁹⁰
~~97~~. (Original) A compound according to Claim ~~50~~,⁴⁵
which is (2R)-4-(3-chloropyridin-2-yl)-N-[4-(2-methoxy-1,1-dimethylethyl)phenyl]-2-methylpiperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

⁹¹
~~98~~. (Original) A compound according to Claim ~~50~~,⁴⁵
which is (2R)-N-[4-(2-methoxy-1,1-dimethylethyl)phenyl]-2-methyl-4-[3-(trifluoromethyl)pyridin-2-yl]piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

⁹²
~~99~~. (Original) A compound according to Claim ~~50~~,⁴⁵
which is (2R)-4-(3-chloropyridin-2-yl)-N-[4-(1-cyano-1-

methylethyl)phenyl]-2-methylpiperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

~~93~~
100. (Original) A compound according to Claim ~~50~~⁴⁵, which is (2R)-N-[4-(1-cyano-1-methylethyl)phenyl]-2-methyl-4-[3-(trifluoromethyl)pyridin-2-yl]piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

~~94~~
101. (Original) A compound according to Claim ~~50~~⁴⁵, which is N-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl)-2-ethylpiperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

~~95~~
102. (Original) A compound according to Claim ~~50~~⁴⁵, which is 4-(3-chloropyridin-2-yl)-2-ethyl-N-[4-(trifluoromethyl)phenyl]piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

~~96~~
103. (Original) A compound according to Claim ~~50~~⁴⁵, which is 4-(3-chloropyridin-2-yl)-2-ethyl-N-(4-isopropylphenyl)piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

C

~~97~~
104. (Original) A compound according to Claim ~~50~~, ⁴⁵
which is N-(4-tert-butylphenyl)-2-ethyl-4-[3-(trifluoromethyl)pyridin-2-yl]piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

~~98~~
105. (Original) A compound according to Claim ~~50~~, ⁴⁵
which is 2-ethyl-N-[4-(trifluoromethyl)phenyl]-4-[3-(trifluoromethyl)pyridin-2-yl]piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

C1 ~~99~~
106. (Original) A compound according to Claim ~~50~~, ⁴⁵
which is 2-ethyl-N-(4-isopropylphenyl)-4-[3-(trifluoromethyl)pyridin-2-yl]piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

~~100~~
107. (Original) A compound according to Claim ~~50~~, ⁴⁵
which is 2-tert-butyl-N-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl)piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

~~101~~
108. (Original) A compound according to Claim ~~50~~, ⁴⁵
which is 2-tert-butyl-N-[4-(trifluoromethyl)phenyl]-4-[3-

(trifluoromethyl)pyridin-2-yl]piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

¹⁰⁹
~~109~~. (Original) A compound according to Claim ⁴⁵~~50~~, which is N-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl)-2-isopropylpiperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

¹⁰³
~~110~~. (Original) A compound according to Claim ⁴⁵~~50~~, which is N-(4-tert-butylphenyl)-2-isopropyl-4-[3-(trifluoromethyl)pyridin-2-yl]piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

C1
¹⁰⁴
~~111~~. (Original) A compound according to Claim ⁴⁵~~50~~, which is 2-isopropyl-N-[4-(trifluoromethyl)phenyl]-4-[3-(trifluoromethyl)pyridin-2-yl]piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

¹⁰⁵
~~112~~. (Original) A compound according to Claim ⁴⁵~~50~~, which is 2-isopropyl-N-(4-isopropylphenyl)-4-[3-(trifluoromethyl)pyridin-2-yl]piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

C

106

~~113~~. (Original) A compound according to Claim ~~50~~, ⁴⁵
which is (2R)-4-(3-fluoropyridin-2-yl)-2-methyl-N-[4-(trifluoromethyl)phenyl]piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

107

~~114~~. (Original) A compound according to Claim ~~50~~, ⁴⁵
which is (2R)-N-(4-tert-butylphenyl)-4-(3-fluoropyridin-2-yl)-2-methylpiperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

108

~~115~~. (Original) A compound according to Claim ~~50~~, ⁴⁵
which is (2R)-4-(3-fluoropyridin-2-yl)-N-(4-isopropylphenyl)-2-methylpiperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

C1

109

~~116~~. (Original) A compound according to Claim ~~50~~, ⁴⁵
which is (2R)-N-(4-cyclohexylphenyl)-4-(3-fluoropyridin-2-yl)-2-methylpiperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

110

~~117~~. (Original) A compound according to Claim ~~50~~, ⁴⁵
which is (2R)-N-(4-cyclopentylphenyl)-4-(3-fluoropyridin-2-

C

yl)-2-methylpiperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

~~118~~¹¹⁸. (Original) A compound according to Claim ~~50~~⁴⁵, which is (2R)-N-(4-tert-butylphenyl)-4-(3-cyanopyridin-2-yl)-2-methylpiperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

~~119~~¹¹⁹. (Original) A compound according to Claim ~~50~~⁴⁵, which is (2R)-4-(3-cyanopyridin-2-yl)-2-methyl-N-[4-(trifluoromethyl)phenyl]piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

C1
~~120~~¹²⁰. (Original) A compound according to Claim ~~50~~⁴⁵, which is (2R)-4-(3-chloropyridin-2-yl)-N-{4-[cyano(phenyl)methyl]phenyl}-2-methylpiperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

~~121~~¹²¹. (Original) A compound according to Claim ~~50~~⁴⁵, which is (2R)-4-(3-chloropyridin-2-yl)-2-methyl-N-[3-methyl-4-(trifluoromethyl)phenyl]piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

¹¹⁵
~~122~~. (Original) A compound according to Claim ~~50~~, ⁴⁵

which is (2R)-4-(3-fluoropyridin-2-yl)-2-methyl-N-[3-methyl-4-(trifluoromethyl)phenyl]piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

¹¹⁶
~~123~~. (Original) A compound according to Claim ~~50~~, ⁴⁵

which is (2R)-4-{3-[bis(methylsulfonyl)amino]pyridin-2-yl}-N-(4-tert-butylphenyl)-2-methylpiperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

¹¹⁷
~~124~~. (Original) A compound according to Claim ~~50~~, ⁴⁵

C1 which is (2R)-2-methyl-N-[3-methyl-4-(trifluoromethyl)phenyl]-4-[3-(trifluoromethyl)pyridin-2-yl] piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

¹¹⁸
~~125~~. (Original) A compound according to Claim ~~50~~, ⁴⁵

which is (2R)-4-(3-chloropyridin-2-yl)-2-methyl-N-{4-[1-(trifluoromethyl)vinyl]phenyl} piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

¹¹⁹
~~126~~. (Original) A compound according to Claim ~~50~~, ⁴⁵

which is (2R)-2-methyl-4-[3-(trifluoromethyl)pyridin-2-yl]-

C

N-{4-[1-(trifluoromethyl)vinyl] phenyl}piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

¹²⁰
~~127~~. (Original) A compound according to Claim ⁴⁵~~50~~,
which is (2R)-4-(3-fluoropyridin-2-yl)-2-methyl-N-{4-[1-(trifluoromethyl)vinyl] phenyl}piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

¹²⁷
~~128~~. (Original) A compound according to Claim ⁴⁵~~50~~,
which is (2R)-N-(4-sec-butylphenyl)-4-(3-fluoropyridin-2-yl)-2-methylpiperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

C1 ¹²⁹
~~129~~. (Original) A compound according to Claim ⁴⁵~~50~~,
which is (2R)-2-methyl-N-[4-(2,2,2-trifluoro-1-methylethyl)phenyl]-4-[3-(trifluoromethyl)pyridin-2-yl]piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

¹²⁸
~~130~~. (Original) A compound according to Claim ⁴⁵~~50~~,
which is (2R)-4-(3-fluoropyridin-2-yl)-2-methyl-N-[4-(2,2,2-trifluoro-1-methylethyl)phenyl]piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

¹²⁴
~~131~~. (Original) A compound according to Claim ~~50~~, ⁴⁵
which is (2R)-4-(3-chloro-5-nitropyridin-2-yl)-2-methyl-N-
[4-(trifluoromethyl)phenyl]piperazine-1-carboxamide, or a
pharmaceutically acceptable salt thereof.

¹²⁵
~~132~~. (Original) A compound according to Claim ~~50~~, ⁴⁵
which is (2R)-4-(5-amino-3-chloropyridin-2-yl)-2-methyl-N-
[4-(trifluoromethyl)phenyl]piperazine-1-carboxamide, or a
pharmaceutically acceptable salt thereof.

C1 ¹²⁶
~~133~~. (Original) A compound according to Claim ~~50~~, ⁴⁵
which is (2R)-4-(3-fluoropyridin-2-yl)-N-[3-fluoro-4-
(trifluoromethyl) phenyl]-2-methylpiperazine-1-carboxamide,
or a pharmaceutically acceptable salt thereof.

¹²⁷
~~134~~. (Original) A compound according to Claim ~~50~~, ⁴⁵
which is (2R)-N-[3-fluoro-4-(trifluoromethyl)phenyl]-2-
methyl-4-[3-(trifluoromethyl) pyridin-2-yl]piperazine-1-
carboxamide, or a pharmaceutically acceptable salt thereof.

¹²⁸
~~135~~. (Original) A compound according to Claim ~~50~~, ⁴⁵
which is (2R)-4-(3-chloropyridin-2-yl)-2-methyl-N-[4-

(2,2,2-trifluoro-1-methylethyl)phenyl]piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

¹²⁹
~~130~~
~~136~~. (Original) A compound according to Claim ⁴⁵~~50~~, which is (2R)-4-(3-chloropyridin-2-yl)-2-methyl-N-(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

¹³⁰
~~137~~. (Original) A compound according to Claim ⁴⁵~~50~~, which is (2R)-4-(3-fluoropyridin-2-yl)-2-methyl-N-(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

C1
¹³¹
~~138~~. (Original) A compound according to Claim ⁴⁵~~50~~, which is (2R)-2-methyl-N-(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)-4-[3-(trifluoromethyl)pyridin-2-yl]piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

¹³²
~~139~~. (Original) A compound according to Claim ⁴⁵~~50~~, which is (2R)-4-[3-(aminosulfonyl)pyridin-2-yl]-N-(4-tert-butylphenyl)-2-methylpiperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

C

²
~~132~~
~~140~~. (Original) A compound according to Claim ⁴⁵~~50~~,
which is (2R)-N-(4-benzoylphenyl)-4-(3-chloropyridin-2-yl)-
2-methylpiperazine-1-carboxamide, or a pharmaceutically
acceptable salt thereof.

¹³⁸
~~141~~. (Original) A compound according to Claim ⁴⁵~~50~~,
which is (2R)-4-(3-chloropyridin-2-yl)-N-(4-iodophenyl)-2-
methylpiperazine-1-carboxamide, or a pharmaceutically
acceptable salt thereof.

C1
¹³⁵
~~142~~. (Original) A compound according to Claim ⁴⁵~~50~~,
which is (2R)-4-(3-chloropyridin-2-yl)-2-methyl-N-{4-
[2,2,2-trifluoro-1,1-
bis(trifluoromethyl)ethyl]phenyl}piperazine-1-carboxamide,
or a pharmaceutically acceptable salt thereof.

¹³⁶
~~143~~. (Original) A compound according to Claim ⁴⁵~~50~~,
which is (2R)-2-methyl-N-{4-[2,2,2-trifluoro-1,1-
bis(trifluoromethyl)ethyl]phenyl}-4-[3-
(trifluoromethyl)pyridin-2-yl]piperazine-1-carboxamide, or
a pharmaceutically acceptable salt thereof.

¹³⁷
~~144~~. (Original) A compound according to Claim ⁴⁵~~50~~,
which is (2R)-N-(4-butylphenyl)-4-(3-chloropyridin-2-yl)-2-methylpiperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

¹³⁸
~~145~~. (Original) A compound according to Claim ⁴⁵~~50~~,
which is 2-(fluoromethyl)-N-[4-(trifluoromethyl)phenyl]-4-[3-(trifluoromethyl)pyridin-2-yl]piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

C1 ¹³⁹
~~146~~. (Original) A compound according to Claim ⁴⁵~~50~~,
which is (2R)-N-[4-bromo-3-(trifluoromethyl)phenyl]-4-(3-chloropyridin-2-yl)-2-methylpiperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

¹⁴⁰
~~147~~. (Original) A compound according to Claim ⁴⁵~~50~~,
which is (2R)-N-[4-bromo-3-(trifluoromethyl)phenyl]-2-methyl-4-[3-(trifluoromethyl)pyridin-2-yl]piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

¹⁴¹
~~148~~. (Original) A compound according to Claim ⁴⁵~~50~~,
which is (2R)-4-(3-chloropyridin-2-yl)-N-[4-fluoro-3-

(trifluoromethyl) phenyl]-2-methylpiperazine-1-carboxamide,
or a pharmaceutically acceptable salt thereof.

~~148~~
~~149~~. (Original) A compound according to Claim ~~50~~,⁴⁵
which is (2R)-N-[4-fluoro-3-(trifluoromethyl) phenyl]-2-
methyl-4-[3-(trifluoromethyl) pyridin-2-yl] piperazine-1-
carboxamide, or a pharmaceutically acceptable salt thereof.

~~149~~
~~150~~. (Original) A compound according to Claim ~~50~~,⁴⁵
which is (2R)-4-(3-chloropyridin-2-yl)-2-methyl-N-{4-
C 1 [1,2,2,2-tetrafluoro-1-(trifluoromethyl)ethyl]
phenyl}piperazine-1-carboxamide, or a pharmaceutically
acceptable salt thereof.

~~149~~
~~151~~. (Original) A compound according to Claim ~~50~~,⁴⁵
which is (2R)-2-methyl-N-{4-[1,2,2,2-tetrafluoro-1-
(trifluoromethyl) ethyl]phenyl}-4-[3-
(trifluoromethyl)pyridin-2-yl]piperazine-1-carboxamide, or
a pharmaceutically acceptable salt thereof.

~~149~~
~~152~~. (Original) A compound according to Claim ~~40~~,³⁵
which is (2R)-N-(4-tert-butylphenyl)-4-(3-chloropyrazin-2-

yl)-2-methylpiperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

¹⁴⁶
~~153~~. (Original) A compound according to Claim ³⁵~~40~~,
which is (2R)-4-(3-chloropyrazin-2-yl)-N-(4-isopropylphenyl)-2-methylpiperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

¹⁴⁷
~~154~~. (Original) A compound according to Claim ³⁵~~40~~,
which is (2R)-4-(3-chloropyrazin-2-yl)-2-methyl-N-[4-(trifluoromethyl)phenyl]piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

¹⁴⁸
~~155~~. (Original) A compound according to Claim ³⁵~~40~~,
which is (2R)-4-(3-chloropyrazin-2-yl)-2-methyl-N-{4-[1,2,2,2-tetrafluoro-1-(trifluoromethyl)ethyl] phenyl} piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

¹⁴⁹
~~156~~. (Original) A compound according to Claim ³⁵~~40~~,
which is (2R)-4-(3-chloropyrazin-2-yl)-2-methyl-N-{4-cyclopentyl-phenyl} piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

C

¹⁵⁰
~~157~~. (Original) A compound according to Claim ~~40~~³⁶,
which is (2R)-4-(3-chloropyrazin-2-yl)-2-methyl-N-{4-cyclohexyl-phenyl} piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.


¹⁵¹
~~158~~. (Original) A compound according to Claim ~~42~~³⁷,
which is 4-(3-chloropyridin-2-yl)-N-[5-(trifluoromethyl)pyridin-2-yl]piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

C1
¹⁵²
~~159~~. (Original) A compound according to Claim ~~42~~³⁷,
which is (2R)-4-(3-chloropyridin-2-yl)-2-methyl-N-[5-(trifluoromethyl)pyridin-2-yl]piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

¹⁵³
~~160~~. (Original) A compound according to Claim ~~42~~³⁷,
which is (2R)-4-(3-chloropyridin-2-yl)-2-methyl-N-[6-(trifluoromethyl)pyridin-3-yl]piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

154

161. (Previously Amended) A compound of the Formula:



or a pharmaceutically acceptable salt thereof, wherein:

A is absent or is selected from the group consisting of O,

S, NR_A , $\text{CR}_B\text{R}_B'$, $\text{NR}_A\text{CR}_B\text{R}_B'$, $\text{CR}_B\text{R}_B'\text{NR}_A$, $-\text{CR}_A=\text{CR}_B-$, and C_3H_4 ;

where R_A , R_B , and R_B' are independently selected at each occurrence from hydrogen [or] and C_{1-6} alkyl;

R_3 and R_4 are independently chosen at each occurrence from the group consisting of hydrogen, halogen, cyano, nitro, halo(C_{1-6})alkyl, halo(C_{1-6})alkoxy, hydroxy, amino, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, $-\text{NH}(\text{C}_{1-6}\text{alkyl})$, and $-\text{N}(\text{C}_{1-6}\text{alkyl})(\text{C}_{1-6}\text{alkyl})$;

R_5 is selected from the group consisting of halogen, halo(C_{1-6})alkyl, C_{3-6} alkyl substituted with 0-3 R_6 , C_{2-6} alkenyl substituted with 0-3 R_6 , $(\text{C}_{3-8}\text{cycloalkyl})\text{C}_{1-4}\text{alkyl}$ substituted with 0-3 R_6 , and Y;

R_{5B} and R_{9B} each represent from 0 to 2 substituents and are independently chosen from halogen, cyano, nitro,


C

halo(C₁₋₂)alkyl, halo(C₁₋₂)alkoxy, amino, C₁₋₄alkyl, and C₁₋₂alkoxy;

R₆ is independently selected at each occurrence from the group consisting of cyano, halogen, hydroxy, C₁₋₄alkyl, C₁₋₄alkoxy, -NH(C₁₋₄alkyl), -N(C₁₋₄alkyl)(C₁₋₄alkyl) and Y;

Y is independently selected at each occurrence from C₃₋₈ cycloalkyl, piperidiny, piperazinyl, tetrahydropyranyl, dihydropyranyl, morpholinyl, thiomorpholinyl, phenyl, pyridyl, pyrazinyl, pyrimidinyl, thiazolyl, thienyl, and imidazolyl, each of which may be further substituted with one or more substituents independently selected from halogen, oxo, hydroxy, amino, nitro, cyano, C₁₋₄alkyl, C₁₋₄alkoxy, halo(C₁₋₄)alkyl, halo(C₁₋₄)alkoxy, mono- or di(C₁₋₄)alkylamino, and C₁₋₄alkylthio.

154 ¹⁵⁵
~~154~~ 162. (Original) A compound or salt according to Claim
161 of the Formula:



wherein

C

R₄ is independently selected at each occurrence from hydrogen and C₁₋₄alkyl.

¹⁵⁶
~~153~~. (Original) A compound or salt according to Claim ¹⁵⁶
~~152~~, wherein:

R₅ is selected from the group consisting of halo(C₁₋₆)alkyl, C₃₋₆alkyl, (C₃₋₈cycloalkyl)C₁₋₄alkyl, and Y;

R_{5B} and R_{9B} each represent from 0 to 1 substituents and are independently chosen from halogen, cyano, nitro, halo(C₁₋₂)alkyl, halo(C₁₋₂)alkoxy, amino, C₁₋₄alkyl, and C₁₋₂alkoxy;

C1
Y is selected from C₃₋₈ cycloalkyl, piperidinyl, piperazinyl, tetrahydropyranyl, dihydropyranyl, morpholinyl, thiomorpholinyl, phenyl, pyridyl, pyrazinyl, pyrimidinyl, thiazolyl, thienyl, and imidazolyl.

¹⁵⁷
~~154~~. (Original) A compound according to Claim ¹⁵⁴
~~151~~, which is (2R)-4-isoquinolin-1-yl-2-methyl-N-[4-(trifluoromethyl)phenyl]piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.


¹⁵⁸
~~165~~. (Original) A compound according to Claim ~~161~~,¹⁵⁴
which is (2R)-N-(4-tert-butylphenyl)-4-isoquinolin-1-yl-2-methylpiperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

¹⁵⁹
~~166~~. (Original) A compound according to Claim ~~161~~,¹⁵⁴
which is (2R)-N-(4-isopropylphenyl)-4-isoquinolin-1-yl-2-methylpiperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

C1
¹⁶⁰
~~167~~. (Original) A compound according to Claim ~~161~~,¹⁵⁴
which is (2R)-N-(4-cyclopentylphenyl)-4-isoquinolin-1-yl-2-methylpiperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

¹⁶¹
~~168~~. (Original) A compound according to Claim ~~161~~,¹⁵⁴
which is (2R)-N-(4-cyclohexylphenyl)-4-isoquinolin-1-yl-2-methylpiperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

169
~~169~~. (Previously Amended) A compound of the Formula:



or a pharmaceutically acceptable salt thereof, wherein:

C1
A is absent or is selected from the group consisting of O, S, NR_A , $\text{CR}_B\text{R}_B'$, $\text{NR}_A\text{CR}_B\text{R}_B'$, $\text{CR}_B\text{R}_B'\text{NR}_A$, $-\text{CR}_A=\text{CR}_B-$, and C_3H_4 ; where R_A , R_B , and R_B' are independently selected at each occurrence from hydrogen and C_{1-6} alkyl;

R_3 and R_4 are independently chosen at each occurrence from the group consisting of hydrogen, halogen, cyano, nitro, halo(C_{1-6})alkyl, halo(C_{1-6})alkoxy, hydroxy, amino, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, $-\text{NH}(\text{C}_{1-6}\text{alkyl})$, and $-\text{N}(\text{C}_{1-6}\text{alkyl})(\text{C}_{1-6}\text{alkyl})$;


R_{5B} , R_{5C} , and R_{9B} each represent from 0 to 2 substituents and are independently chosen from halogen, cyano, nitro, halo(C_{1-2})alkyl, halo(C_{1-2})alkoxy, amino, C_{1-4} alkyl, and C_{1-2} alkoxy; and

R_9 is selected from the group consisting of halogen, cyano, $-\text{N}(\text{SO}_2\text{CH}_3)_2$, $-\text{SO}_2\text{NH}_2$, halo(C_{1-3})alkyl, C_{1-3} alkoxy, $-\text{NH}(\text{C}_{1-3}\text{alkyl})$, and $-\text{N}(\text{C}_{1-3}\text{alkyl})(\text{C}_{1-3}\text{alkyl})$.

~~163~~
170. (Original) A compound or salt according to Claim

~~169~~ of the Formula:

~~169~~



wherein

R₄ is independently selected at each occurrence from hydrogen and C₁₋₄alkyl.

~~164~~

171. (Original) A compound or salt according to Claim

~~163~~
~~170~~, wherein:

R₉ is selected from the group consisting of halogen and halo(C₁₋₂)alkyl; and

R_{5B} and R_{9B} each represent from 0 to 1 substituents and are independently chosen from halogen, cyano, nitro, halo(C₁₋₂)alkyl, halo(C₁₋₂)alkoxy, amino, C₁₋₄alkyl, and C₁₋₂alkoxy.

~~165~~

172. (Original) A compound according to Claim ~~169~~,

which is (2R)-4-(3-chloropyridin-2-yl)-N-(9H-fluoren-2-yl)-

C

2-methylpiperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

¹⁶⁶
~~173~~. (Original) A compound according to Claim ¹⁶⁹~~169~~,
which is (2R)-N-(9H-fluoren-2-yl)-2-methyl-4-[3-(trifluoromethyl)pyridin-2-yl]piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

¹⁶⁸
~~174~~. (Original) A compound according to Claim ³³~~38~~,
which is (2R)-N-(4-tert-butylcyclohexyl)-4-(3-chloropyridin-2-yl)-2-methylpiperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

¹⁶⁸
~~175~~. (Original) A compound according to Claim ³³~~38~~,
which is (2R)-4-(3-chloropyridin-2-yl)-N-(4-isopropylcyclohexyl)-2-methylpiperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

¹⁶⁹
~~176~~. (Original) A compound according to Claim ³³~~38~~,
which is (2R)-N-(4-isopropylcyclohexyl)-2-methyl-4-[3-(trifluoromethyl)pyridin-2-yl]piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

[177-192. (Cancelled)]


~~170~~

~~193.~~ (Original) A compound or salt of Claim ~~50~~⁴⁵ wherein the compound or salt is not addictive.

[194-196. (Cancelled)]

~~171~~

~~197.~~ (Original) A compound of the Formula:



or a pharmaceutically acceptable salt thereof wherein:

R₄ is methyl or hydrogen;


R_{9B} represents 0-2 substituents independently chosen from:

halogen, cyano, nitro, halo(C₁₋₂)alkyl, halo(C₁₋₂)alkoxy, amino, C₁₋₄alkyl, and C₁₋₂alkoxy; and

Ar₁ is 2,4-dichlorophenyl or 3-nitro-4-chlorophenyl.

~~172~~

~~198.~~ (Original) A compound of the Formula:



or a pharmaceutically acceptable salt thereof wherein:

R₉ is chloro or trifluoromethyl; and

R_{5B} and R_{9B} independently represent from 0-2 substituents on each of the rings on which they occur and are independently chosen from: halogen, cyano, nitro, halo(C₁₋₂)alkyl, halo(C₁₋₂)alkoxy, amino, C₁₋₄alkyl, and C₁₋₂alkoxy.

17B
199. (Previously added) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound or salt according to claim 4.

17B
200. (Previously added) A package comprising a pharmaceutical composition of claim 199 in a container and further comprising indicia comprising instructions for using the composition to alleviate pain.

175

201. (Previously added) A package comprising a pharmaceutical composition of claim ~~189~~¹⁷³ in a container and further comprising indicia comprising instructions for using the composition to alleviate symptoms of exposure to capsaicin or tear gas.

176

202. (Previously added) A compound or salt of claim ~~4~~¹ wherein, in an *in vitro* assay of capsaicin receptor antagonism, the compound or salt exhibits capsaicin receptor antagonist activity, but in an *in vitro* assay of capsaicin receptor agonism the compound does not exhibit detectable agonist activity.

177

203. (Previously added) A compound or salt of claim ~~4~~¹ wherein a dose of the compound or salt that is twice the minimum dose sufficient to provide analgesia in an animal model for determining pain relief does not produce sedation in an animal model assay of sedation.

178

204. (Previously added) 4-(3-Chloro-2-pyridinyl)-N-[4-(isopropyl)phenyl]-1-piperazinecarboxamide or a pharmaceutically acceptable salt thereof.

C

179

~~180~~

205. (Previously added) (2R)-N-(4-tert-butylphenyl)-4-[3-(dimethylamino)pyridin-2-yl]-2-methylpiperazine-1-carboxamide or a pharmaceutically acceptable salt thereof.

180

~~206~~

(Previously added) (2R)-4-[3-(dimethylamino)pyridin-2-yl]-2-methyl-N-[4-(trifluoromethyl)phenyl]piperazine-1-carboxamide or a pharmaceutically acceptable salt thereof.

C1

181

~~207~~

(Previously added) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound or salt according to claim ²²~~21~~.

182

~~208~~

(Previously added) A compound or salt of claim ²²~~21~~ wherein, in an *in vitro* assay of capsaicin receptor antagonism, the compound or salt exhibits capsaicin receptor antagonist activity, but in an *in vitro* assay of capsaicin receptor agonism the compound does not exhibit detectable agonist activity.

183

~~209~~

(Previously added) A compound or salt of claim ²²~~21~~ wherein a dose of the compound or salt that is twice the minimum dose sufficient to provide analgesia in an animal

C

model for determining pain relief does not produce sedation in an animal model assay of sedation.

C1
¹⁸⁴
~~210~~. (Previously added) A package comprising a pharmaceutical composition of claim ¹⁸⁴~~207~~ in a container and further comprising indicia comprising instructions for using the composition to alleviate pain.

¹⁸⁵
~~211~~. (Previously added) A package comprising a pharmaceutical composition of claim ¹⁸⁴~~207~~ in a container and further comprising indicia comprising instructions for using the composition to alleviate symptoms of exposure to capsaicin or tear gas.
